Endoprosthesis devices and methods of using the same

ABSTRACT

Endoprosthesis assemblies and methods for using the same. In at least one embodiment, the endoprosthesis assembly comprises an endoprosthesis comprising an impermeable inner wall defining an endoprosthesis lumen sized and shaped to permit fluid to flow therethrough, a distal balloon positioned at or near a distal end of the endoprosthesis and capable of inflation to anchor the distal end of the endoprosthesis within a luminal organ, and a proximal balloon positioned at or near a proximal end of the endoprosthesis and capable of inflation to anchor the proximal end of the endoprosthesis within the luminal organ, wherein when the endoprosthesis assembly is positioned within the luminal organ at or near an aneurysm sac, inflation of the distal balloon and the proximal balloon effectively isolates the aneurysm sac and prevents fluid within the aneurysm sac from flowing past the distal balloon and the proximal balloon.

PRIORITY

The present application is related to, claims the priority benefit of,and is a U.S. continuation patent application of, U.S. patentapplication Ser. No. 15/646,586, filed Jul. 11, 2017 and issued as U.S.Pat. No. 10,258,458 on Apr. 16, 2019, which is related to, claims thepriority benefit of, and is a U.S. continuation patent application of,U.S. patent application Ser. No. 15/070,104, filed Mar. 15, 2016 andissued as U.S. Pat. No. 9,700,402 on Jul. 11, 2017, which is related to,claims the priority benefit of, and is a U.S. continuation patentapplication of, U.S. patent application Ser. No. 14/258,881, filed Apr.22, 2014 and issued as U.S. Pat. No. 9,283,098 on Mar. 15, 2016, whichis related to, claims the priority benefit of, and is a U.S.continuation patent application of, U.S. patent application Ser. No.13/151,774, filed on Jun. 2, 2011 and issued as U.S. Pat. No. 8,702,789on Apr. 22, 2014, which is related to, claims the priority benefit of,and is a U.S. continuation-in-part patent application of, U.S. patentapplication Ser. No. 12/701,340, filed Feb. 5, 2010 and issued as U.S.Pat. No. 9,050,091 on Jun. 9, 2015, which is related to, claims thepriority benefit of, and is a U.S. continuation-in-part patentapplication of, U.S. patent application Ser. No. 11/997,147, filed Jun.30, 2008 and issued as U.S. Pat. No. 8,398,703 on Mar. 19, 2013, whichis related to, claims the priority benefit of, and is a U.S. nationalstage entry of, International Patent Application Serial No.PCT/US2006/029424, filed Jul. 28, 2006, which is related to, and claimsthe priority benefit of, U.S. Provisional Patent Application Ser. No.60/703,421, filed Jul. 29, 2005. The contents of each of theseapplications and patents are hereby incorporated by reference in theirentirety into this disclosure.

BACKGROUND

The present disclosure relates generally to tissue support, includingdevices and methods for aortic tissue support and for the treatment ofaneurysms.

Aortic aneurysms are formed in a vessel when the wall of the vesselweakens, either due to disease, aging, heredity or some other process.The pressure of the blood flowing through the weakened area causes thevessel wall to balloon out, forming a blood-filled aneurysm sack.Although most aneurysms begin small, they tend to enlarge over time andthe risk of the sack rupturing increases as the aneurysms grows larger.Acute rupture of the aortic aneurysm is a life-threatening event, due tomassive internal bleeding with a mortality rate of 75-80%. According tothe Society of Vascular Surgeons, ruptured aneurysms account for morethan 15,000 deaths in the U.S. each year, making the abdominal aorticaneurysm (AAA) the 13th leading cause of death in the USA. Clearly,early detection and rupture prevention is the key to the final outcomein abdominal aortic aneurysm patient. However, the condition isunder-diagnosed because most patients with AAA are asymptomatic.Consequently, the majority of the anomalies are discovered unexpectedlyduring routine tests or procedures. An estimated 1.7 million Americanshave AAA, but only about 250,000-300,000 patients are diagnosed everyyear.

There is no proven medical treatment for AAA, and surgical repair hasbeen the only common therapeutic option. A standard open repair has beenassociated with significant morbidity and mortality, prolonged recovery,and late complications. Because of these limitations, many patients andtheir physicians choose to defer operative treatment. Recently,endovascular aneurysm repair (EVAR) has become an alternative and somestudies favorably compare endovascular repair with a standard openrepair. However, significant concern exists relating to endovascularrepair and its value is a subject of healthy debate. Endovascularabdominal aortic aneurysm repair has gained acceptance as a minimallyinvasive alternative to open surgery in selected patients. Whilelong-term durability remains uncertain, patients and their physiciansare willing to accept a degree of uncertainty in exchange for dramaticreduction in duration of hospital stay, and need for blood transfusion.Hence, improvements in the current EVAR devices can potentially makethis approach standard for AAA repair.

Most patients diagnosed with AAA are not considered for surgery orendovascular repair unless the aneurysm is at least 5 cm in diameter,the point at which the risk of rupture clearly exceeds the risk ofrepair. Those with a smaller aneurysm are followed closely with regularimaging studies. There has been much speculation over the years aboutthe preventive use of endovascular aneurysm repair in patients withaneurysms smaller than 5 cm, however, vascular surgeons so far have beenreluctant to use EVAR for smaller aneurysms due to the concern about thelong term durability of the technology and the lack of datademonstrating a clear benefit of early intervention. Moreover, althoughEVAR outcomes have improved over the years as physicians gain moreexperience with the procedure, it remains a technically demandingprocedure that requires extensive training and this has limited thenumber of physicians qualified to perform EVAR.

Despite the shortcoming relating to training, a number of endovasculardevices have been evaluated in clinical trials designed to gain approvalfrom governmental agencies. These devices differ with respect to designfeatures, including modularity, metallic composition and the structureof the stent, thickness, porosity, chemical composition of the polymericfabric, methods for attaching the fabric to the stent, and presence orabsence of an active method of fixing the device to the aortic wall withbars or hooks. With consideration of the numbers of structuralvariations between different brands of endovascular devices, it would beremarkable if clinical outcome were not equally dissimilar. Parameterssuch as frequency of endoleak, long-term change in size of the aneurysmsac, reason for device migration and limb thrombosis may be linked tospecific device design features. Hence, any improvements in thedeployment and attachment of stent graft would increase the utility ofEVAR.

Important drivers and limiters of EVAR are playing a big role in thedecision of the treatment. The drivers include: 1) Less invasivecompared to open repair, which translates into shorter hospitalizationand recovery and lower major morbidity; 2) Aging of the population willincrease the incidence and prevalence of AAA and thoracic aorticaneurysm (TAA); 3) Increasingly informed patient population willgenerate strong patient demand for minimally invasive therapy, and 4)Next-generation devices, expected to address wider patient population(including those with thoracic disease) and reduce complicationsrelative to current model. The limiters, on the other hand, include thefollowing: 1) Clinical literature does not support prophylacticendovascular treatment of the small aneurysm with a low risk offracture; 2) High rate of late complication necessitates extensive andpotentially life-long post procedural follow-up (not required for openrepair) and repeat intervention that makes endovascular therapypotentially more costly than open surgery; 3) Current device is notapplicable to full-range of AMA patients; 4) Technical demands of theapproach require devices and time-consuming training that may eliminaterapid adoption of new products, particularly for a specialist with asmaller case load, and 5) Surgical conversion is complicated by thepresence of the stent graft. Improvements in the current devices wouldcertainly make the drivers outweigh the limiters.

The most important trial conducted to date is the EVAR 1 study, whichrandomized over 1,000 elective patients with aneurysms 5.5 cm or largercomparing EVAR to open surgical repair. Thirty-day mortality publishedthis year demonstrated a clear advantage of EVAR (1.6% vs. 4.7% for openrepair). However, EVAR patients had significantly higher rates ofsecondary intervention (9.8% vs. 5.8%). A second version study, EVAR 2,is comparing EVAR with best medical treatment in patients unsuitable forsurgical repair. The 12-month result for EVAR 1 are particularlyimportant, as physicians will be looking to see if endovascular therapyis able, for the first time, to demonstrate significant survival benefitover open surgery after one year.

Despite some of its inherent drawbacks, EVAR is expected to experiencerobust growth over the next several years. The U.S. AAA graft market isprojected to increase from $288M in 2004 to $552M in 2008. In addition,contribution from thoracic graft systems, beginning this year, will growthe total US aortic stent market to over $670M in 2008 (Endovascular,2005).

Ongoing areas of concern with endovascular abdominal aortic repairare; 1) Rate of late complications; 2) Appreciable intervention andconversion rates; 3) Dubious cost advantage compared to open surgery dueto the need of intervention and regular patient monitoring; 4) Increaseddevice failure with time; 5) Increased procedural failure with time, and6) Rupture risk of 1% per year after endovascular repair is notdramatically different from the natural history of small 5 cm aneurysms.Hence, there is high rate of secondary intervention (primarily to treatendoleaks—persistent flow within the aneurysm sac that in certain casescan lead to aneurysm rupture, if left untreated), and increasing rate ofdevice failures over time. In addition to endoleaks, other latecomplications in AAA graft trials include device migration, modularcomponent separation, graft thrombosis, bar separation, and materialfatigue.

Currently in the U.S., about 60,000 abdominal aortic aneurysm (AAA)patients require intervention each year. The majority of the patientsare treated with open surgical repair, while about 40% are treated withEVAR. Although open AAA repair is highly successful, it is alsoextremely invasive, with an operative mortality rate between 5-10%.Thus, patients with significant co-morbidities are generally notcandidates for open repair. These patients are the primary beneficiariesof endovascular grafting or EVAR. EVAR gained tremendous popularity in1990 after commercial AAA stent graft became available in the U.S. Aftera one-year period of adjustment, however, problems with the firstgeneration device began to surface including migration, endoleak andendotension. Although physicians remain confident, they have for themost part recovered from the disappointment associated with the firstgeneration technology and are looking forward to future advances in thefield. Further expansion of endovascular repair is required to improvethe device and good long-term results from large randomized trialscomparing EVAR with open surgery. There is no doubt that a device thatovercomes some of the current shortcomings of EVAR devices such asmigration, endoleak and endotension is greatly welcomed for thetreatment of aortic aneurysm.

Thus, a need exists in the art for an alternative to the conventionalmethods of aneurysm treatment. A further need exist for a reliable,accurate and minimally invasive device or technique of treatinganeurysms and minimizing their risks of enlarging or rupturing.

BRIEF SUMMARY

The current EVAR devices and methods are inadequate. They are prone tosuch fatal problems as migration, endoleak, and endotension. In order toaddress this medical problem, the present disclosure provides devicesand methods for minimizing and/or preventing the growth or rupture ofaneurysms or other vascular growth through the use of magnetic tissuesupport.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly comprises an endograft having aninner wall, an outer wall, and a graft structure positioned between theinner wall and the outer wall, the inner wall of the endograft definingan endograft lumen sized and shaped to permit fluid to flowtherethrough, and a tube defining one or more tube openings, said tubecoupled to the endograft in a configuration whereby the one or more tubeopenings are exposed along the outer wall of the endograft. In anotherembodiment, the tube is coupled to the outer wall of the endograft. Inyet another embodiment, the tube is coupled to the endograft between theinner wall and the outer wall of the endograft. In an additionalembodiment, the endograft further comprises a length, and wherein thetube extends substantially the length of the endograft.

In at least one embodiment of an endograft assembly of the presentdisclosure, the inner wall of the endograft is impermeable to fluids,and wherein the outer wall of the endograft is permeable to fluids. Inanother embodiment, the endograft assembly further comprises a catheterhaving a distal catheter end, a proximal catheter end, and defining alumen therethrough, wherein the distal catheter end of the catheter isconfigured to be removably coupled to a proximal tube end of the tube.In an additional embodiment, the endograft assembly further comprises asuction/infusion source configured to be coupled to the catheter at ornear the proximal catheter end, the suction/infusion source capable ofproviding suction within the lumen of the catheter and further capableof injecting a substance into the lumen of the catheter. In yet anadditional embodiment, the endograft assembly further comprises asuction/infusion source configured to be coupled to the catheter at ornear the proximal catheter end, the suction/infusion source capable ofproviding suction within the lumen of the catheter to facilitate removalof blood present within an aneurysm sac when the endograft assembly ispositioned within a vessel at or near the site of a vessel aneurysm andwhen the catheter is coupled to the tube.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly further comprises a suction/infusionsource configured to be coupled to the catheter at or near the proximalcatheter end, the suction/infusion source capable of injecting asubstance into the lumen of the catheter and into an aneurysm sac whenthe endograft assembly is positioned within a vessel at or near the siteof a vessel aneurysm and when the catheter is coupled to the tube. Inanother embodiment, the substance is capable of forming a cast withinthe aneurysm sac when it is injected to the aneurysm sac, said castproviding structural reinforcement to the vessel aneurysm. In yetanother embodiment, the substance is selected from the group consistingof ethylene vinyl alcohol copolymer, acetate polymer, ethylene vinylalcohol dissolved in dimethyl sulfoxide, cellulose, cyanoacrylate, glue,and gel magnetic polymer.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft comprises a configuration selected from thegroup consisting of a straight configuration and a curved configuration.In an additional embodiment, wherein the tube comprises a proximal tubeend and a distal tube end, and wherein the proximal tube end comprises atube threaded portion. In yet an additional embodiment, the tubethreaded portion corresponds to a catheter threaded portion located at adistal catheter end of a catheter, permitting the catheter to berotatably coupled to the tube. In another embodiment, the catheterfurther comprises a catheter tip at the distal catheter end, thecatheter tip configured to fit within a lumen of the tube. In at leastone embodiment of an endograft assembly of the present disclosure, thetube comprises a proximal tube end and a distal tube end, and whereinthe proximal tube end comprises one or more unidirectional valves. Inanother embodiment, the one or more unidirectional valves permit fluidto flow out of the tube when a catheter is coupled thereto, and whereinthe one or more unidirectional valves prevents fluid from flowing out ofthe tube when the catheter is not coupled thereto. In yet anotherembodiment, the endograft assembly comprises one or more materialsselected from the group consisting of nitinol, plastic, polyurethane,silastic, polyvinylchloride, and polytetrafluoroethylene.

In at least one embodiment of an endograft assembly of the presentdisclosure, the graft structure of the endograft assembly is capable ofa first, collapsed configuration, and is further capable of a second,expanded configuration. In an additional embodiment, the graft structureis selected from the group consisting of a traditional stent, aballoon-expandable device, or an autoexpandable device. In yet anadditional embodiment, the inner wall comprises a fluid-impermeablefabric, and wherein the outer wall comprises a fluid-permeable fabric.In another embodiment, the endograft assembly further comprises a spongesheath having a distal end and a proximal end, the sponge sheath coupledto the outer wall of the endograft and configured to permit blood flowtherethrough. In yet another embodiment, the sponge sheath defines oneor more sponge channels therein, said sponge channels configured topermit fluid flow therethrough.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly comprises an endograft having aninner wall and an outer wall, and a graft structure positioned betweenthe inner wall and the outer wall, the inner wall of the endograftdefining an endograft lumen sized and shaped to permit fluid to flowtherethrough, a tube comprising a proximal tube end, a distal tube end,one or more unidirectional valves at or near the proximal tube end, andone or more tube openings defined along the tube, said tube coupled tothe endograft in a configuration whereby the one or more tube openingsare exposed along the outer wall of the endograft, a catheter having adistal catheter end, a proximal catheter end, and defining a lumentherethrough, wherein the distal catheter end of the catheter isconfigured to be removably coupled to a proximal tube end of the tube,and a suction/infusion source configured to be coupled to the catheterat or near the proximal catheter end, the suction/infusion sourcecapable of providing suction within the lumen of the catheter andfurther capable of injecting a substance into the lumen of the catheter

In at least one embodiment of method for using an endograft assembly ofthe present disclosure, the method comprising the steps of delivering anendograft assembly within a vessel of a patient at or near the site of avessel aneurysm, the endograft assembly comprising an endograft, a tubecoupled to the endograft, the tube defining one or more tube openings, acatheter removably coupled to the tube, and a suction/infusion sourcecoupled to the catheter, operating a suction/infusion source to removeblood present within an aneurysm sac of the vessel aneurysm, andoperating the suction/infusion source to inject a substance into theaneurysm sac to form a cast at or near the site of the vessel aneurysm.In another embodiment, the step of delivering the endograft assemblyfurther comprises the step of deploying the endograft assembly withinthe vessel. In yet another embodiment, the step of operating asuction/infusion source to remove blood present within an aneurysm saccauses a wall of the vessel aneurysm to collapse toward the endograftassembly. In an additional embodiment, the substance is capable offorming a cast within the aneurysm sac when it is injected to theaneurysm sac, said cast providing structural reinforcement to the vesselaneurysm.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly comprises an endograft having aninner wall and an outer wall, and a graft structure positioned betweenthe inner wall and the outer wall, the inner wall of the endograftdefining an endograft lumen sized and shaped to permit fluid to flowtherethrough, and a sponge sheath having a distal end and a proximalend, the sponge sheath coupled to the outer wall of the endograft andconfigured to permit blood flow therethrough. In another embodiment, theinner wall of the endograft is impermeable to fluids, and wherein theouter wall of the endograft is permeable to fluids. In yet anotherembodiment, the sponge sheath defines one or more sponge channelstherein, said sponge channels configured to permit fluid flowtherethrough.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly further comprises a reservoir bagcoupled to the sponge sheath at or near the proximal end of the spongesheath, said reservoir bag capable of receiving fluid from the spongesheath and the one or more sponge channels. In another embodiment, theendograft assembly further comprises a catheter having a distal catheterend, a proximal catheter end, and defining a lumen therethrough, whereinthe distal catheter end of the catheter is configured to be removablycoupled to the reservoir bag. In yet another embodiment, the endograftassembly further comprises a suction/infusion source configured to becoupled to the catheter at or near the proximal catheter end, thesuction/infusion source capable of providing suction within the lumen ofthe catheter and further capable of injecting a substance into the lumenof the catheter. In an additional embodiment, the endograft assemblyfurther comprises a suction/infusion source configured to be coupled tothe catheter at or near the proximal catheter end, the suction/infusionsource capable of providing suction within the lumen of the catheter tofacilitate removal of blood present within an aneurysm sac when theendograft assembly is positioned within a vessel at or near the site ofa vessel aneurysm and when the catheter is coupled to the reservoir bag.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly further comprises a suction/infusionsource configured to be coupled to the catheter at or near the proximalcatheter end, the suction/infusion source capable of injecting asubstance into the lumen of the catheter and into an aneurysm sac whenthe endograft assembly is positioned within a vessel at or near the siteof a vessel aneurysm and when the catheter is coupled to the reservoirbag. In another embodiment, the substance is capable of forming a castwithin the aneurysm sac when it is injected to the aneurysm sac, saidcast providing structural reinforcement to the vessel aneurysm. In yetanother embodiment, the substance is selected from the group consistingof ethylene vinyl alcohol copolymer, acetate polymer, ethylene vinylalcohol dissolved in dimethyl sulfoxide, cellulose, cyanoacrylate, glue,and gel magnetic polymer.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft comprises a configuration selected from thegroup consisting of a straight configuration and a curved configuration.In another embodiment, the reservoir bag comprises a reservoir bagthreaded portion. In yet another embodiment, the reservoir bag threadedportion corresponds to a catheter threaded portion located at a distalcatheter end of a catheter, permitting the catheter to be rotatablycoupled to the reservoir bag. In an additional embodiment, the catheterfurther comprises a catheter tip at the distal catheter end, thecatheter tip configured to fit within a lumen of the reservoir bag.

In at least one embodiment of an endograft assembly of the presentdisclosure, the reservoir bag comprises one or more unidirectionalvalves. In an additional embodiment, the one or more unidirectionalvalves permit fluid to flow out of the reservoir bag when a catheter iscoupled thereto, and wherein the one or more unidirectional valvesprevents fluid from flowing out of the reservoir bag when the catheteris not coupled thereto. In yet an additional embodiment, the endograftassembly comprises one or more materials selected from the groupconsisting of plastic, polyurethane, silastic, polyvinylchloride, andpolytetrafluoroethylene. In another embodiment, the endograft assemblyis capable of a first, collapsed configuration, and wherein theendograft assembly is capable of a second, expanded configuration. Inyet another embodiment, the sponge sheath comprises one or morematerials selected from the group consisting of cellulose fiber, woodfiber, foamed plastic polymer, polyurethane, silastic, rubber,polytetrafluoroethylene, synthetic sponge, natural sponge, low-densitypolyether, polyvinyl alcohol, and polyester.

In at least one embodiment of an endograft assembly of the presentdisclosure, the endograft assembly comprises an endograft having aninner wall and an outer wall, and a graft structure positioned betweenthe inner wall and the outer wall, the inner wall of the endograftdefining an endograft lumen sized and shaped to permit fluid to flowtherethrough, a sponge sheath having a distal end and a proximal end,the sponge sheath coupled to the outer wall of the endograft andconfigured to permit blood flow therethrough, the sponge sheath definingone or more sponge channels configured to permit fluid flowtherethrough, a reservoir bag coupled to the sponge sheath at or nearthe proximal end of the sponge sheath, said reservoir bag capable ofreceiving fluid from the sponge sheath and the one or more spongechannels, a catheter having a distal catheter end, a proximal catheterend, and defining a lumen therethrough, wherein the distal catheter endof the catheter is configured to be removably coupled to the reservoirbag, and a suction/infusion source configured to be coupled to thecatheter at or near the proximal catheter end, the suction/infusionsource capable of providing suction within the lumen of the catheter andfurther capable of injecting a substance into the lumen of the catheter.

In at least one embodiment of a method for using an endograft assemblyof the present disclosure, the method comprises the steps of deliveringan endograft assembly within a vessel of a patient at or near the siteof a vessel aneurysm, the endograft assembly comprising an endograft, asponge sheath coupled to the endograft, the sponge sheath defining oneor more sponge channels, a reservoir bag coupled to the sponge sheath,said reservoir bag capable of receiving fluid from the sponge sheath andthe one or more sponge channels, a catheter removably coupled to thereservoir bag, and a suction/infusion source coupled to the catheter,operating a suction/infusion source to remove blood present within ananeurysm sac of the vessel aneurysm, and operating the suction/infusionsource to inject a substance into the aneurysm sac to form a cast at ornear the site of the vessel aneurysm. In another embodiment, the step ofdelivering the endograft assembly further comprises the step ofdeploying the endograft assembly within the vessel. In yet anotherembodiment, the step of operating a suction/infusion source to removeblood present within an aneurysm sac causes a wall of the vesselaneurysm to collapse toward the endograft assembly. In an additionalembodiment, the substance is capable of forming a cast within theaneurysm sac when it is injected to the aneurysm sac, said castproviding structural reinforcement to the vessel aneurysm.

In at least one embodiment of an endoprosthesis assembly of the presentdisclosure, the endoprosthesis assembly comprises an endoprosthesiscomprising an impermeable inner wall defining an endoprosthesis lumensized and shaped to permit fluid to flow therethrough, a distal balloonpositioned at or near a distal end of the endoprosthesis, the distalballoon capable of inflation to anchor the distal end of theendoprosthesis within a luminal organ, and a proximal balloon positionedat or near a proximal end of the endoprosthesis, the proximal ballooncapable of inflation to anchor the proximal end of the endoprosthesiswithin the luminal organ, wherein when the endoprosthesis assembly ispositioned within the luminal organ at or near an aneurysm sac,inflation of the distal balloon and the proximal balloon effectivelyisolates the aneurysm sac and prevents fluid within the aneurysm sacfrom flowing past the distal balloon and the proximal balloon and intoother areas of vasculature adjacent to the aneurysm sac. In anotherembodiment, the endoprosthesis assembly further comprises a first tubedefining one or more first tube openings, the first tube coupled to anoutside of the inner wall of the endoprosthesis in a first configurationwhereby the one or more first tube openings arc exposed along theoutside of the inner wall of the endoprosthesis.

In at least one embodiment of an endoprosthesis assembly of the presentdisclosure, the endoprosthesis further comprises an outer wall adjacentto the inner wall, the outer wall configured to permit fluid to flowtherethrough. In an additional embodiment, the endoprosthesis assemblyfurther comprises a first tube defining one or more first tube openings,the first tube positioned within the outer wall of the endoprosthesis ina first configuration whereby the one or more first tube openings areexposed within the outer wall of the endoprosthesis. In yet anadditional embodiment, the endoprosthesis assembly further comprises afirst tube defining one or more first tube openings, the first tubepositioned adjacent to the outer wall of the endoprosthesis in a firstconfiguration whereby the one or more first tube openings are exposedalong the outer wall of the endoprosthesis. In another embodiment, theendoprosthesis assembly further comprises a first tube defining one ormore first tube openings, the first tube positioned at or within theouter wall of the endoprosthesis in a first configuration whereby theone or more first tube openings are exposed at or near the outer wall ofthe endoprosthesis, and a second tube defining one or more second tubeopenings, the second tube positioned at or within the outer wall of theendoprosthesis in a second configuration whereby the one or more secondtube openings are exposed at or near the outer wall of theendoprosthesis. In yet another embodiment, the first configuration is arelative “S” configuration along at least half of a distance between thedistal end and the proximal end of the endoprosthesis, and wherein thesecond configuration is a circumferential configuration at or near thedistal end of the endoprosthesis.

In at least one embodiment of an endoprosthesis assembly of the presentdisclosure, the endoprosthesis assembly further comprises a graftstructure positioned adjacent to the inner wall of the endoprosthesis,the graft structure capable of expansion to expand the endoprosthesis.In another embodiment, the endoprosthesis assembly further comprises acatheter having a distal catheter end, a proximal catheter end, anddefining a suction/infusion lumen therethrough and aninflation/deflation lumen therethrough, wherein the distal catheter endof the catheter is configured to be removably coupled to theendoprosthesis at or near the proximal end of the endoprosthesis. In yetanother embodiment, the endoprosthesis assembly further comprises asuction/infusion source configured to be coupled to the catheter at ornear a proximal catheter end, the suction/infusion source capable ofproviding suction within the suction/infusion lumen of the catheter andfurther capable of injecting a substance into the suction/infusion lumenof the catheter. In an additional embodiment, the substance is capableof forming a cast within the aneurysm sac when it is injected to theaneurysm sac, said cast providing structural reinforcement to a vesselwall surrounding the aneurysm sac. In yet an additional embodiment, theendoprosthesis assembly further comprises a suction/infusion sourceconfigured to be coupled to the catheter at or near a proximal catheterend, the suction/infusion source capable of providing suction within thesuction/infusion lumen of the catheter to facilitate removal of bloodpresent within the aneurysm sac when the endoprosthesis assembly ispositioned within the luminal organ at or near the aneurysm sac and whenthe catheter is coupled to the endoprosthesis.

In at least one embodiment of an endoprosthesis assembly of the presentdisclosure, the endoprosthesis assembly further comprises a valvemechanism coupled to the endoprosthesis, the valve mechanism configuredto receive a distal catheter end of a catheter, the valve mechanismfurther configured to permit fluid to flow in and out of the valvemechanism when the catheter is coupled thereto, the valve mechanismfurther configured to prevent fluid from flowing in and out of the valvemechanism when the catheter is not coupled thereto. In an additionalembodiment, the endoprosthesis assembly further comprises a magneticmechanism coupled to the endoprosthesis assembly at or near the distalend of the endoprosthesis, the magnetic mechanism configured to attracta second magnetic mechanism of a second endoprosthesis assemblypositioned relative to the endoprosthesis assembly. In yet an additionalembodiment, the distal balloon has a configuration selected from thegroup consisting of a 360° configuration around the endoprosthesis,about a 180° configuration around the endoprosthesis, about a 270°configuration around the endoprosthesis, and a configuration betweenabout 180° and about 360° around the endoprosthesis. In anotherembodiment, the one or more first tube openings are positioned aboutapproximately half of a relative side of the endoprosthesis. In yetanother embodiment, the endoprosthesis assembly further comprises apressure sensor coupled thereto, the pressure sensor operable to obtainat least one pressure measurement of an environment surrounding theendoprosthesis.

In at least one embodiment of an endoprosthesis assembly of the presentdisclosure, the endoprosthesis assembly further comprises a secondendoprosthesis comprising a second impermeable inner wall defining asecond endoprosthesis lumen sized and shaped to permit fluid to flowtherethrough, a second distal balloon positioned at or near a seconddistal end of the second endoprosthesis, the second distal ballooncapable of inflation to anchor the second distal end of the secondendoprosthesis within the luminal organ, and a second proximal balloonpositioned at or near a second proximal end of the secondendoprosthesis, the second proximal balloon capable of inflation toanchor the second proximal end of the second endoprosthesis within thesecond luminal organ, wherein when the distal end of the endoprosthesisis positioned distal to the aneurysm sac of the luminal organ, theproximal end of the endoprosthesis is configured to be positioned withina first luminal organ bifurcation of the luminal organ, wherein when thesecond distal end of the second endoprosthesis is positioned distal tothe aneurysm sac of the luminal organ, the second proximal end of thesecond endoprosthesis is configured to be positioned within a secondluminal organ bifurcation of the luminal organ, and wherein inflation ofthe distal balloon, the second distal balloon, the proximal balloon, andthe second proximal balloon effectively isolates the aneurysm sac distalto the aneurysm sac within an unbifurcated portion of the luminal organand proximal to the aneurysm sac within the first luminal organbifurcation and the second luminal organ bifurcation. In anotherembodiment, the endoprosthesis assembly further comprises a firstmagnetic mechanism coupled to the endoprosthesis assembly at or near thedistal end of the endoprosthesis, and a second magnetic mechanismcoupled to the second endoprosthesis assembly at or near the seconddistal end of the second endoprosthesis, wherein the first magneticmechanism and the second magnetic mechanism are configured to attractone another when positioned relative to one another.

In at least one embodiment of an endoprosthesis system of the presentdisclosure, the endoprosthesis system further comprises a firstendoprosthesis assembly and a second endoprosthesis assembly, each ofthe first endoprosthesis assembly and the second endoprosthesis assemblycomprising an endoprosthesis comprising an impermeable inner walldefining an endoprosthesis lumen sized and shaped to permit fluid toflow therethrough, a distal balloon positioned at or near a distal endof the endoprosthesis, the distal balloon capable of inflation to anchorthe distal end of the endoprosthesis within a luminal organ, and aproximal balloon positioned at or near a proximal end of theendoprosthesis, the proximal balloon capable of inflation to anchor theproximal end of the endoprosthesis within the luminal organ, a firsttube defining one or more first tube openings, the first tube positionedat or within the outer wall of the endoprosthesis in a firstconfiguration whereby the one or more first tube openings are exposed ator near the outer wall of a relative side of the endoprosthesis, whereinwhen the first endoprosthesis assembly and the second endoprosthesisassembly are positioned within the luminal organ adjacent to one anotherat or near an aneurysm sac, inflation of each of the distal balloons andeach of the proximal balloons effectively isolates the aneurysm sac andprevents fluid within the aneurysm sac from flowing past the distalballoons and the proximal balloons and into other areas of vasculatureadjacent to the aneurysm sac. In another embodiment, the endoprosthesissystem further comprises a first catheter and a second catheter, each ofthe first catheter and the second catheter having a distal catheter end,a proximal catheter end, and defining a suction/infusion lumentherethrough and an inflation/deflation lumen therethrough, wherein thedistal catheter ends of the catheters are configured to be removablycoupled to each individual endoprosthesis, respectively, at or near theproximal ends of each endoprosthesis. In yet another embodiment, theendoprosthesis system further comprises a first valve mechanism and asecond valve mechanism, each valve mechanism coupled to eachendoprosthesis, respectively, each valve mechanism configured to receivea distal catheter end of a catheter, each valve mechanism furtherconfigured to permit fluid to flow in and out of each valve mechanismwhen each catheter is coupled thereto, each valve mechanism furtherconfigured to prevent fluid from flowing in and out of each valvemechanism when each catheter is not coupled thereto. In an additionalembodiment, the endoprosthesis system further comprises a first magneticmechanism and a second magnetic mechanism, each magnetic mechanismcoupled to each distal end of each endoprosthesis, respectively, whereinthe first magnetic mechanism and the second magnetic mechanism areconfigured to attract one another when positioned relative to oneanother.

In at least one embodiment of a method for using an endoprosthesisassembly, the method comprises the steps of delivering an endoprosthesisassembly within a vessel of a patient at or near the site of a vesselaneurysm sac of a vessel aneurysm, the endoprosthesis assemblycomprising an endoprosthesis comprising an impermeable inner walldefining an endoprosthesis lumen sized and shaped to permit fluid toflow therethrough, a distal balloon positioned at or near a distal endof the endoprosthesis, the distal balloon capable of inflation to anchorthe distal end of the endoprosthesis within a luminal organ, a proximalballoon positioned at or near a proximal end of the endoprosthesis, theproximal balloon capable of inflation to anchor the proximal end of theendoprosthesis within the luminal organ, and a catheter having a distalcatheter end, a proximal catheter end, and defining a suction/infusionlumen therethrough and an inflation/deflation lumen therethrough,wherein the distal catheter end of the catheter is configured to beremovably coupled to the endoprosthesis at or near the proximal end ofthe endoprosthesis, operating an inflation/deflation source incommunication with the inflation/deflation lumen of the catheter toinflate the distal balloon and the proximal balloon to isolate theaneurysm sac and prevent fluid within the aneurysm sac from flowing pastthe distal balloon and the proximal balloon and into other areas ofvasculature adjacent to the aneurysm sac, operating a suction/infusionsource in communication with the suction/infusion lumen of the catheterto remove blood present within the aneurysm sac, and operating thesuction/infusion source to inject a substance into the aneurysm sac toform a cast at or near the vessel aneurysm. In another embodiment, themethod further comprises the steps of operating the inflation/deflationsource in communication with the inflation/deflation lumen of thecatheter to deflate the distal balloon and the proximal balloon,disconnecting the catheter from the endoprosthesis, and removing thecatheter from the patient. In yet another embodiment, the step ofdelivering the endoprosthesis assembly further comprises the step ofdeploying the endoprosthesis assembly within the vessel.

In at least one embodiment of a method for using an endoprosthesisassembly, the step of operating a suction/infusion source to removeblood present within the aneurysm sac causes a wall of the vesselaneurysm to collapse toward the endoprosthesis assembly. In anotherembodiment, the step of operating a suction/infusion source to removeblood is performed along with a step of obtaining a first pressuremeasurement using a pressure sensor in communication with the aneurysmsac so to avoid negative pressure within the aneurysm sac, and whereinthe step of operating a suction/infusion source to inject a substance isperformed along with a step of obtaining a second pressure measurementusing the pressure sensor so to avoid excessive pressure within theaneurysm sac. In an additional embodiment, the step of delivering anendoprosthesis assembly further comprises delivering a secondendoprosthesis assembly within the vessel of the patient at or near thesite of the vessel aneurysm sac of the vessel aneurysm, the secondendoprosthesis assembly comprising a second endoprosthesis comprising asecond impermeable inner wall defining a second endoprosthesis lumensized and shaped to permit fluid to flow therethrough, a second distalballoon positioned at or near a second distal end of the secondendoprosthesis, the second distal balloon capable of inflation to anchorthe second distal end of the second endoprosthesis within a luminalorgan, a second proximal balloon positioned at or near a second proximalend of the second endoprosthesis, the second proximal balloon capable ofinflation to anchor the second proximal end of the second endoprosthesiswithin the luminal organ, and a second catheter having a second distalcatheter end, a second proximal catheter end, and defining a secondsuction/infusion lumen therethrough and a second inflation/deflationlumen therethrough, wherein the second distal catheter end of the secondcatheter is configured to be removably coupled to the secondendoprosthesis at or near the second proximal end of the secondendoprosthesis, and wherein the step of operating theinflation/deflation source is performed to also inflate the seconddistal balloon and the second proximal balloon to isolate the aneurysmsac and prevent fluid within the aneurysm sac from flowing past thesecond distal balloon and the second proximal balloon and into otherareas of vasculature adjacent to the aneurysm sac. In yet an additionalembodiment, the step of delivering an endoprosthesis assembly isperformed to position the proximal end of the endoprosthesis within afirst luminal organ bifurcation of the luminal organ and to position thesecond proximal end of the second endoprosthesis within a second luminalorgan bifurcation of the luminal organ.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a front view of a magnetically stabilized luminal stentgraft assembly with two magnetic bodies according to an exemplaryembodiment of the present disclosure;

FIG. 2 shows an angled view of a luminal stent graft with a magneticcovering and powder according to an exemplary embodiment of the presentdisclosure;

FIG. 3A shows a front view of a luminal stent graft embedded withmagnetic beads or particles surrounded by a stabilizing magnetic body toprevent distension of the aneurysmic region according to an exemplaryembodiment of the present disclosure;

FIG. 3B shows a cross-section of FIG. 3A to emphasize axial support ofthe diseased region;

FIG. 4 shows T₁₁ changes with a maximum of T₁₁=42.826 KPa θ=0° and 180°in the inner circular) and minimum of T₁₁=−42.826 KPa (θ=90° and 270° inthe inner circular) according to an exemplary embodiment of the presentdisclosure;

FIG. 5 shows a front view of a luminal stent graft within an aneurysmincorporating a perforated tube for controlling the fluid environmentwithin the aneurysm and an optional pressure sensor as part of atelemetry system according to an exemplary embodiment of the presentdisclosure;

FIGS. 6A-6D show endograft assemblies according to exemplary embodimentsof the present disclosure;

FIG. 6E shows a block diagram of various components of an endograftassembly according to an exemplary embodiment of the present disclosure;

FIG. 7 shows a diagram of a method for using an endograft assemblyaccording to an exemplary embodiment of the present disclosure;

FIGS. 8A-8C show an endograft assembly positioned within a bodily vesselaccording to an exemplary embodiment of the present disclosure;

FIGS. 9A-9C show a connection and disconnection of a removable catheterand a tube of an endograft assembly according to an exemplary embodimentof the present disclosure;

FIG. 10 shows an endograft assembly comprising a sponge sheath accordingto an exemplary embodiment of the present disclosure;

FIGS. 11A-12B show portions of endograft assemblies comprising a spongesheath according to exemplary embodiments of the present disclosure;

FIGS. 13A-13C show a connection and disconnection of a removablecatheter and a reservoir bag of an endograft assembly according to anexemplary embodiment of the present disclosure;

FIG. 14 shows a diagram of a method for using an endograft assemblyaccording to an exemplary embodiment of the present disclosure;

FIGS. 15A and 15B show an endograft assembly positioned within a bodilyvessel according to an exemplary embodiment of the present disclosure;

FIGS. 16 and 17 show perspective front views of endoprosthesisassemblies according to exemplary embodiments of the present disclosure;

FIGS. 18A-18D show views of endoprosthesis assemblies according toexemplary embodiments of the present disclosure positioned within aluminal organ;

FIG. 19 shows a diagram of method steps of a method for using anendoprosthesis assembly according to an exemplary embodiment of thepresent disclosure;

FIGS. 20A and 20B show front views of endoprosthesis assembliesaccording to exemplary embodiments of the present disclosure;

FIG. 21 shows endoprosthesis assemblies according to exemplaryembodiments of the present disclosure positioned within a luminal organ;

FIG. 22 shows a block diagram of various components of an exemplaryembodiment of an endoprosthesis assembly of the present disclosure; and

FIG. 23 shows another block diagram of various components of anexemplary embodiment of an endoprosthesis assembly of the presentdisclosure.

DETAILED DESCRIPTION

The disclosure of the present application provides various endograft andendoprosthesis devices and methods for using the same. For the purposesof promoting an understanding of the principles of the presentdisclosure, reference will now be made to the embodiments illustrated inthe drawings, and specific language will be used to describe the same.It will nevertheless be understood that no limitation of the scope ofthis disclosure is thereby intended.

As discussed briefly above, the aneurysm size appears to be the one ofthe most important factors determining risk of aneurysm rupture. Changesin aneurysm dimension have been used as a surrogate marker for clinicalefficacy after endovascular repair. Other morphological changes,including progressive angulation, and aortic neck enlargement, may occurin response to either aneurysm exclusion or associated degenerativechanges in adjacent segments, respectively. In endovascular repair, theaneurysm sac is left intact and, as a consequence, this feature plays animportant role in outcome assessment, defining the success or failure ofaneurysm exclusion. Long term aneurysm exclusion and devicestabilization is dependent on the maintenance of an effectiveattachment, connection, or seal between the endograft and the hostaorta. Therefore dilatation of the aorta at the site or sites intendedfor primary endograft fixation may lead to treatment failure either withdevice migration or via the occurrence of a new endoleak with aneurysmexpansion. The use of magnets as described in the present disclosure isintended to reduce the neck enlargement and remodeling since the magnetwill distribute the stress more uniformly unlike the stent that posestress concentration which induce vascular remodeling.

Endoleak is defined by the persistence of blood flow outside the lumenof the endoluminal graft but within the aneurysm sac, as determined byan imaging study. An endoleak is evidence of incomplete exclusion of theaneurysm from the circulation and may be the result of an incompleteseal between the endograft and the blood vessel wall, an inadequateconnection between components of a modular prosthesis, fabric defects orporosity, or retrograde blood flow from patent aortic side branches.Hence, an adhesive force at the neck of the stent may minimize orprevent endoleak (type I).

Endoleaks, including their detection, potential clinical significance,and treatment remain an active area of investigation. However, althoughit is now evident that an endoleak may resolve spontaneously, aproportion of those that do persist have been associated with lateaneurysm rupture. Endoleaks classification include:

-   -   1. Type I:        -   a) Inadequate seal at the proximal end of endograft        -   b) Inadequate seal at the distal end of endograft        -   c) Inadequate seal at the iliac occluder plug    -   2. Type II: Flow from visceral vessels (lumbar, IMA, accessory        renal, Hypogastric) without attachment site connection.    -   3. Type III:        -   a) Flow from module disconnection        -   b) Flow from fabric disruption (Minor<2 mm, Major>2 mm)    -   4. Type IV: Flow from porous fabric (<30 days after graft        placement)

There are also endoleaks of undefined origins where flow is visualizedbut the source is unidentified.

Endotension. It is now appreciated as AAA may continue to enlarge afterendovascular repair, even in the absence of detectable endoleak, andthat this enlargement may lead to aneurysm rupture. Explanation forpersistence or recurrent pressurization of an aneurysm sac includesblood flow that is below the sensitivity limits for detection withcurrent imaging technology, or pressure transmission through thrombus,or endograft fabric. On physical examination, the aneurysm may bepulsatile and intrasac measurements may reveal pressure that approach orequal to systemic values. A magnetic device according to the presentdisclosure that provides sufficient “seal” at the two necks of theaneurysm and along the body of the aneurysm would eliminate endoleakstype I and II.

Migration. Migration is defined by clinical and radiographic parameters,as a caudal movement of the proximal attachment site or cranial movementof a distal attachment site. A device is considered to have migrated ifat least 10 mm of movement was noted relative to anatomic landmarks, apatient experiences a symptom from migration, irrespective of distance,or a secondary intervention was undertaken to remedy migration-relatedproblems, irrespective of distance. An adhesive force with sufficientshear component would also eliminate migration. Hence, one of theadvantages of the present disclosure is the development of amagnet-based anchoring device at the two ends of the graft thatovercomes endoleak and migration.

In biomedical engineering, the electromagnetic effect on biologicalcells has diverse applications such as MRI, bypass surgery, andMEMS-related devices. Static and time-dependent fields are used in thediagnosis and treatment of human disease. MRI involves using a largemagnetic field to image structure. The therapeutic benefits of lowfrequency magnetic fields have been shown to induce gene expression andupregulate the heat shock protein. Recently, magnets are advocated foruse in vascular coupling for distal anastomosis in bypass surgery, whichhas lead to a multi-center clinical trial. To date, most of themagneto-static research on biological cells is investigated by usinganalytic or numerical finite difference methods.

The fundamental equations governing the interaction between current andmagnetic-flux density can be found in any classic textbook. In general,those equations are complex due to the fact that matter possesses agreat variety of properties. For example, if the body of interest iselastic, then a change of shape, volume and temperature can appear.Also, if the sum of all forces acting on the body is not zero,translational or rotational acceleration may occur. Therefore, it isimportant to calculate the Magnetostatic forces and couple theMagnetostatic forces with other physical effects in order to determinethe deformation, rotation, displacement and so on in the matter. In thepresent application, the force balance including the Maxwell's force isanalyzed and simulated based on the distribution of the magnetic-fluxdensity. The coupled formulation of the magnetic field and the surfacestress balance for treatment of aortic aneurysm is demonstrated.

In general, the magnetic field intensity is not curl-free and,therefore, we cannot describe magnetic field intensity in terms of ascalar function. However, there are a number of important applicationsin magnetics in which a magnetic field exists, but there are no currentdensities involved. The most obvious are those involving permanentmagnets. Here we consider a concentric annulus of the stent graftinternal to the vessel lumen and the permanent magnetic ring external tothe vessel wall as shown in FIG. 1 . Since the magnetic ring does notcover the entire circumference of the vessel (covers 0 to 270°), thesolution must be numerical. To design the geometry and magneticproperties of the two poles of the magnet (stent and magnetic ring) toproduce the necessary Maxwell force acting on the aortic tissue thatprevents migration, and endoleak.

A three-dimensional Laplace's equation describes the solution for thepotential field in cylindrical coordinates (ρ, Φ, z)

$\begin{matrix}{{\frac{\partial^{2}\Phi}{\partial\rho^{2}} + {\frac{1}{\rho}\frac{\partial\Phi}{\partial\rho}} + {\frac{1}{\rho^{2}}\frac{\partial^{2}\Phi}{\partial\phi^{2}}} + \frac{\partial^{2}\Phi}{\partial z^{2}}} = 0} & (1)\end{matrix}$

The separation of variables is accomplished by the substitution:Φ(ρ,ϕ,z)=R(ρ)Q(Φ)Z(z)  (2)

This leads to three ordinary differential equations:

$\begin{matrix}{{\frac{d^{2}Z}{{dz}^{2}} - {k^{2}Z}} = 0} & \left( {3a} \right) \\{{\frac{d^{2}Q}{d\;\phi^{2}} + {v^{2}Q}} = 0} & \left( {3b} \right) \\{{\frac{d^{2}R}{d\;\rho^{2}} + {\frac{1}{\rho}\frac{dR}{d\;\rho}} + {\left( {k^{2} - \frac{v^{2}}{\rho^{2}}} \right)R}} = 0} & \left( {3c} \right)\end{matrix}$

The solutions of the first two equations are elementary:Z(z)=e ^(±kz)  (4a)Q(ϕ)=e ^(±vϕ)  (4b)

The radial equation can be put in a standard form by the change ofvariable x=kρ. Then it becomes

$\begin{matrix}{{\frac{d^{2}R}{{dx}^{2}} + {\frac{1}{x}\frac{dR}{dx}} + {\left( {1 - \frac{v^{2}}{x^{2}}} \right)R}} = 0} & (5)\end{matrix}$

This is Bessel's equation, and the solutions are called Bessel functionsof order υ. When υ=m is an integer and k is a constant to be determined.The radial factor isR(ρ)=CJ _(m)(kρ)+DN _(m)(kρ)  (6)

Finally, we getΦ(ρ,ϕ,z)=(Ae ^(±kz))(i Be^(±vϕ))[CJ _(m)(kρ)+DN _(m)(kρ)]  (7)where A, B, and C are the unknown constant. If we combine equation (7)and boundary conditions, we can solve any type of magnetic field betweenthe partial (0° to 270°) concentric annulus.

When the distribution of the magnetic field is known, the Maxwell'sstress tensor can be calculated by the following formulation after thecoordinate system transformation from the cylindrical coordinate to therectangular coordinate.

$\begin{matrix}{T_{ij} = {\frac{1}{\mu}\left\lbrack {{B_{i}B_{j}} - {\frac{1}{2}B^{2}\delta_{ij}}} \right\rbrack}} & (8)\end{matrix}$

(Maxwell's Stress Tensor)

where T_(ij): Maxwell's stress tensor [N/M², Newton/square meter);δ_(ij): Kronecker delta; B_(j): magnetic-flux density T, Tesla or Wb/m²,weber/meter²]; H_(i)=μB_(i); magnetic field intensity [N/(A·m),weber/(ampere·meter)]; δ_(ij)=1 if i=j; δ_(ij)=0 if i≠j.

In Matrix form,

$\begin{matrix}{T_{ij} = \begin{bmatrix}{{\mu\; H_{x}^{2}} - {\frac{1}{2}\mu{H}^{2}}} & {\mu\; H_{x}H_{y}} & {\mu\; H_{x}H_{z}} \\{\mu\; H_{x}H_{y}} & {{\mu\; H_{y}^{2}} - {\frac{1}{2}\mu{H}^{2}}} & {\mu\; H_{y}H_{z}} \\{\mu\; H_{x}H_{z}} & {\mu\; H_{y}H_{z}} & {{\mu\; H_{z}^{2}} - {\frac{1}{2}\mu{H}^{2}}}\end{bmatrix}} & (9)\end{matrix}$

(Maxwell's Stress Tensor)

Once the Maxwell's stress tensor is computed, the equilibrium forcebalance in the surface layer of the artery may be presented.

(Equilibrium Equation for Static Case)σ_(ji,j) +T _(ji,j) +f _(i)=0  (10)where σ_(ji) is the stress tensor [N/M², Newton/square meter] and f_(i)is the force [N/M³, Newton/cubic meter].

Once the Maxwell stress is computed, we must calculate the Maxwellforce. Elementary theory relates magnetostatic forces to changes in thetotal magnetic field energy when infinitesimal virtual displacements aremade between magnetic elements.

$\begin{matrix}{F = {\frac{\partial}{\partial R}{\int{\frac{B \cdot H}{2}{dv}}}}} & (11)\end{matrix}$

An alternative method using the Maxwell Stress Tensor allowsmagnetostatic forces to be calculated directly without approximating thelimit of a virtual displacement. Instead, integration of the stresstensor T_(ij) over any surface enclosing the object will give the netforce acting on it directly if we assume that the permeability of thesurrounding tissue (vessel wall and blood) is significantly differentthan that of the permanent magnets. If n is the outward normal to thesurface, the Maxwell force may be computed as follows:F=∫T _(ij) ·nds  (12)

Expanding the dot product T_(ij)·n allows the force integral equation(12) to be written explicitly as

$\begin{matrix}{\left. {{\left. {F = {{\frac{1}{\mu_{0}}{\oint{\left\lbrack {B \cdot n} \right)B}}} - {\frac{1}{2}B^{2}n}}} \right\rbrack{ds}} = {{\mu_{0}{\oint{\left\lbrack {H \cdot n} \right)H}}} - {\frac{1}{2}H^{2}n}}} \right\rbrack{ds}} & (13)\end{matrix}$

The stress vectorP=μ ₀[H·n)H−1/2H ² n]  (14)does not generally point along H. However for the two extreme cases ofthe H field either normal or parallel to the surface, the forces areeither attractive or repulsive across the surface. But when the fieldcrosses the surface at any other angle than 0° or 90°, there will be ashear component to the force which acts in the plane of the surface.When 3-D axis migration occurs, the magnetic fields H will change sothat the axis force will be created in order to prevent the migration.This requires numerical method such as the FEM simulation.

An exemplary embodiment of the present disclosure as used in graftassembly 100 is shown in FIG. 1 . Assembly 100 includes magnetic bodies110 and magnetic polymer graft 111. In this embodiment, the magneticbodies 110 may be situated at the proximal and distal ends of magneticpolymer graft 111 which may be positioned distal to the renal arteries123 and proximal to the common iliac arteries 122 as shown in FIG. 1 .The magnetic bodies 110 may cover part or the entire circumference ofthe abdominal aorta 120. The magnetic bodies 110 are shown to bering-shaped in FIG. 1 , but they can be any other shape (e.g.,staple-shaped, etc.) as long as they are able to provide a sufficientmagnetic attractive force on the magnetic polymer graft 111 to stabilizethe magnetic polymer graft 111 on the inner surface of the aorta 120.

The magnetic polymer graft 111 may be situated inside the abdominalaorta 120 or the aneurysmic sac 121 and the magnetic bodies 110 may besituated external to the wall of the abdominal aorta 120 or theaneurysmic sac 121 as shown in FIG. 1 . The magnetic bodies 110 may becomposed of a material such that they produce a high magnetic field witha low mass and should be stable against demagnetization. When aferromagnetic material is magnetized in one direction, it will not relaxback to zero magnetization when the imposed magnetizing field isremoved. The amount of magnetization it retains at zero driving field isdefined as remanence. The amount of reverse driving field required todemagnetize it is called coercivity. Some compositions of ferromagneticmaterial will retain an imposed magnetization indefinitely and areuseful as permanent magnets. NdFeB (Neodymium Iron Boron) is an exampleof a permanent magnet used in biological applications includingsutureless vascular anastomosis with magnets.

The magnetic bodies 110 may stabilize the magnetic polymer graft 111 atthe proximal and distal ends of the magnetic polymer graft 111 therebypreventing movement of the magnetic polymer graft 111 or endoleak orendotension. The magnetic polymer graft 111 may be uniformly composed ofa metallic material commonly used in the medical arts such that themagnetic bodies 110 may exert an attractive force on the metallicmaterial such that the magnetic polymer graft 111 is held in position bythe magnetic bodies 110 on the proximal and distal ends of the magneticpolymer graft 11 as illustrated in FIG. 1 . Alternatively, the magneticpolymer graft 111 may be composed of metallic material only at itsproximal and distal ends such that the magnetic bodies 110 may beproperly positioned to exert an attractive force on these proximal anddistal ends of magnetic polymer graft 111. In this variation, the bodyof the magnetic polymer graft 111 may be mesh-like and may be composedof any material commonly used in the medical stenting arts (e.g.,polytetrafluoroethylene-PTFE) such that it can house the metallicmaterial at its proximal and distal ends. The magnetic polymer graft 111may act as a stent by providing a structural passageway for blood toflow down the abdominal aorta 120 while avoiding contact with theaneurysmic sac 121.

A number of different delivery methods may be used to introduce themagnetic bodies 110 in place. Such methods are also applicable to theother exemplary embodiments presented below. Various delivery methodsinclude, but are not limited to: (a) an abdominal laparoscopic procedure(AAA) or thoracoscopic procedure (TAA); (b) a minimal surgicalprocedure; or (c) an open surgical procedure. Other methods andprocedures are apparent to one having ordinary skill in the art afterconsideration of the present exemplary embodiments and are, thus, withinthe scope of the present disclosure.

Another exemplary embodiment of the present disclosure is presented asassembly 200 and is shown in FIG. 1 Assembly 200 depicts a magneticpolymer graft 211 which includes a magnet cover 212, bonded magnetpowder 213, and a graft lumen 214. The bonded magnet powder 213 of themagnetic polymer graft 211 may be composed of any material commonly usedin the medical magnetic arts. The graft lumen 214 may be formed usingmaterials commonly used in the medical stent arts (e.g.,polytetrafluoroethylene—PTFE). The graft lumen 214 may allow blood topass through its material and thereby prevent contact with the aneurysm(not shown) and it may be of such a diameter as to achieve the optimalor desired volume of blood flow through the aneurysm.

The magnetic polymer graft 211 may interact with magnetic bodies (notshown) situated on the external wall of the abdominal aorta or aorticaneurysm (not shown). In this way, the magnetic polymer graft 213 can beheld in place by the attractive force being exerted on it by themagnetic bodies (not shown). Thus, the bonded magnet powder 213 can besituated inside a magnet cover 212 which may be the external layer ofthe magnetic polymer graft 211. The magnet cover 212 may act to protectand confine the magnet powder 213 and further serve to make contact withthe inside of the abdominal aorta or aortic aneurysm. This configurationwould provide the bonded magnetic powder 213 maximum communication withthe magnetic bodies (not shown) situated on the external wall of theabdominal aorta or aortic aneurysm. The magnetic polymer graft 211 maybe inserted through endovascular procedure into the patient therebyavoiding the complications associated with other invasive techniques.

Yet another exemplary embodiment of the present disclosure as shown ingraft assembly 300 is presented in FIG. 3A. Assembly 300 includesmagnetic body 310 and magnetic polymer graft 311. The magnetic body 310is depicted as being ring-shaped in FIG. 3A but it may be any othershape as described above. The magnetic body 310 may cover part or theentire circumferential surface of the abdominal aorta 320. In the lattercase, the magnetic body 310 may partially ensheathe the abdominal aorta320 such that the magnetic body 310 is provided with enough surface areato interact with the magnetic polymer graft 311 on the inside of theabdominal aorta 320 thereby allowing a sufficient magnetic force to beapplied to the magnetic polymer graft 311. The directional arrows 351illustrate the manner in which the magnetic body 310 may ensheathe theabdominal aorta 320 (e.g., circumferentially) to allow for optimalinteraction between the magnetic body 310 and the magnetic polymer graft311.

FIG. 3B shows a cross-section of assembly 300. The lumen 352 of thegraft 311 may provide a conduit for the blood to flow through theaneurysmic sac (not shown) such that the blood flow does not contact theaneurysmic sac (not shown). The outer surface of the abdominal aorta 320may be in physical contact with the magnetic body 310 as illustrated inFIG. 3B. The magnetic polymer graft 311 may make physical contact withthe inner surface of the abdominal aorta 320 such that the magneticpolymer graft 311 is fitted tightly enough against the inner surface ofthe abdominal aorta 320 in order to prevent blood leakage out of thegraft 311 and into the aneurysmic sac (not shown) via space between theproximal portion of the graft 311 and the inner surface of the abdominalaorta 320. This particular embodiment may also prevent endoleak type IIand may further incorporate magnetic beads or particles 363 along thebody of graft composite as shown in FIG. 3B. Application of magneticbody 310 external to the abdominal aorta 320 in the form of gel or glueon the adventitial surface may also provide a restrictive force whichwill prevent expansion of aorta against endoleak type II or endotension.

In this embodiment, we may consider the magnetic flux density B, whichplays the significant role in the computation of attraction forces. Themagnetic polymer graft 311 may include, for examples polymer-bondedNd—Fe—B magnets (BNP-8) by compression moulding (polymer-bonding: magnetpowders are mixed with a polymer carrier matrix, such as epoxy). Themagnetic bodies 310 are formed in a certain shape, when the carrier issolidified, which has residual induction Br (0.6-0.65 Teslas or6000-6500 Gauss); the ring consists of, for example, Heusler alloy(Fe₈₀B₂₀), which has the saturation magnetic flux density of 0.1257Teslas (=1257 Gauss); or consists of carbon-coated metal particles,which has saturation magnetization exceeding about 120 emu/g (saturationmagnetic flux density equal to or approximately 0.15 Teslas). Theproperties provide sufficient force to support the abdominal aorta 320.

An exemplary measurement of the stress tension exerted on the bloodvessel and the changes in T₁₁ (Maxwell's stress tensor wherein i=1 andj=1) are shown in FIG. 4 according to an exemplary embodiment of thepresent disclosure. The maximum stress tension is exerted on the vesselat 401 and 403 while the minimum stress tension is exerted on the vesselat 402 and 404 when an exemplary embodiment of the present disclosure isused to stabilize the graft to the inside wall of the vessel by placingmagnetic bodies on the external surface of the vessel. This calculationdemonstrates that the stress levels are within biologically acceptableranges. In other words, the stress distribution demonstrates that thecomputed Maxwell stresses are well within the physiological range oftissue stress and should not harm the tissue. Hence, the presentdisclosure does not overly perturb the vessel wall and should not inducean injury response or remodeling.

Another embodiment of the present disclosure comprises a graft assembly500 as shown in FIG. 5 . An exemplary assembly 500, as shown in FIG. 5 ,includes magnetic bodies 510, magnetic polymer graft 511, tube 515 withtube openings 516, a catheter 517, and an optional pressure sensor 518.Tube 515 with tube openings 516 may function to suck or siphon outaccumulated blood and/or other tissue or matter and to collapse the wallof aneurysmic sac 521 to decrease blood-clot volume, which may reducethe stress in aneurysmic sac 521 after deployment of magnetic bodies 510and decrease the risk of aneurysmic rupture.

Catheter 517 may be connected to tube 515 from the femoral artery suchthat a user is able to suction out accumulated blood and/or othermatter. Alternatively, tube 515 and tube openings 516 may function as anembolization device such that a biocompatible liquid polymer (e.g.,ethylene vinyl alcohol copolymer, cellulose, acetate polymer,cyanoacrylates or glue gel magnetic powder, or the like) may beintroduced into aneurysmic sac 521 via catheter 517 and through tubeopenings 516 in order to pack aneurysmic sac 521 and thereby reduce thepossibility of endoleak or endotension.

Tube 515 may be situated as shown in FIG. 5 on the outer surface ofmagnetic polymer graft 511 in a coiled configuration. Tube 515 may havetube openings 516 situated on the length of tube 515, and may be spacedapart and of such a diameter so that tube openings 516 may optimallyfunction as described above. Additionally, tube openings 516 may be aslit or any other geometric shape including, but not limited to, apyramid, in order to maximize the functioning of tube openings 516 aspreviously described.

In order to ensure efficient deployment of magnetic polymer graft 511and magnetic bodies 510 (e.g., tight seal at the distal and proximalends), it would be desirable to measure pressure in aneurysmic sac 521.An optional pressure sensor 518 may be situated on the outer surface ofmagnetic polymer graft 511 via mounting or gluing. Optional pressuresensor 518 may be in communication with an external telemetry monitoringsystem (not shown) via a wireless communication system (not shown).Optional pressure sensor 518 may be used to indicate whether or not asuccessful deployment of magnetic polymer graft 511 has been achieved.In this case, the measured pressure will yield a pulsatile tracinginitially before deployment of magnetic bodies 510 and magnetic polymergraft 511. Once magnetic bodies 511 secure the proximal and distal endsof aneurysmic sac 521, a tight seal between magnetic bodies 510 and thesurface of aneurysmic sac 521 would eliminate the pulsatile tracing.This would provide indication of successful deployment. This can equallyapply to the current art of stent grafts without magnets.

Optional pressure sensor 518 may also be used to monitor the patient'saneurysm by measuring the pressure within aneurysmic sac 521. It maymonitor the interior pressure of aneurysmic sac 521 by measuring thelocal pressure outside of the wall of magnetic polymer graft 511 andinside the outstretched wall of aneurysmic sac 521. This would be oftremendous clinical value as the physician can monitor the status ofaneurysmic sac 521 and adapt treatment according to aneurysmic behavior.Currently, expensive and complicated imaging methods (such as MRI andCT) are used to monitor the dimension of the aneurysm longitudinally atdiscreet times (annually, etc.). Pressure is more relevant mechanicallyas a predictor of rupture and with telemetry it can be monitoredcontinuously.

An additional embodiment of an endograft assembly of the presentdisclosure is shown in FIG. 6A. As shown in FIG. 6A, endograft assembly600 comprises an endograft 602 having an inner wall 604, an outer wall606, and a graft structure 603 positioned therebetween. Graft structure603, in at least one embodiment, may be mesh-like and may be composed ofany material commonly used in the medical stenting arts (e.g., variouspolymers and metals, including but not limited to PTFE). Graft structure603, in various embodiments, may comprise a traditional stent, aballoon-expandable device, or an autoexpandable device. Inner wall 604and outer wall 606 may comprise a fabric as described herein, or maycomprise one or more other materials capable of permitting orprohibiting fluid flow therethrough as referenced herein. Inner wall 604and outer wall 606 may be positioned a distance from one another, topermit graft structure 603 to be positioned therebetween, and further topermit a tube 515 having tube openings 516 to be positionedtherebetween.

Inner wall 604 also defines an endograft lumen 605, as shown in FIG. 6A,permitting blood flow through a vessel when endograft assembly 600 ispositioned therein. Tube openings 516 within tube 515 are effectivelyexposed along the outer wall 606 of endograft 602, whereby, for example,tube 515 has a sealed portion for passing from the walls of endograft602 into a space outside of endograft 602. In another exemplaryembodiment, tube 515 is incorporated into outer wall 606 so that tubeopenings 516 of tube 515 are exposed along the outer wall 606. In atleast one embodiment, inner wall 604 is impermeable to fluids (i.e.,blood), and outer wall 606 is permeable to fluids, including blood.Endograft 602 may comprise any number of additional features thattypically or occasionally accompany endografts.

As shown in FIG. 6A, the proximal end 608 of tube 515 may be removablycoupled to a distal end 610 of removable catheter 612. Asuction/infusion source (not shown) may be coupled to the removablecatheter 612 at or near the distal end 610 of removable catheter 612, sothat fluid present in, for example, an aneurysm sac, may be removed byapplying suction to or within removable catheter 612 so that the fluidmay enter tube openings 516 of tube 515 as described herein.

Additional embodiments of endograft assemblies 600 of the presentdisclosure are shown in FIGS. 6B-6D. In FIG. 6B, an exemplary endograftassembly 600 is shown in a collapsed configuration to permit, forexample, insertion of endograft assembly 600 into a vessel. FIG. 6Cshows an exemplary embodiment of an endograft assembly 600 of thepresent disclosure in an open or deployed configuration so thatendograft assembly 600 may be used within the body as referenced herein.In at least one embodiment, endograft assembly 600 may be opened ordeployed by way of moving/pulling a portion of endograft assembly 600relative to another portion, similar to the deployment of a stent, sothat graft structure 603 of endograft 602 may expand from a collapsedconfiguration. In at least this example, tube 515 is incorporated intoor positioned upon outer wall 606, so that tube openings 516 of tube 515are exposed along the outer wall 606 of endograft 602. Such an exemplaryendograft assembly 600 may be useful in connection with, for example,treating an abdominal aortic aneurysm. In addition, and as shown in FIG.6C, removable catheter 612 is coupled to tube 515, with a sealedentrance of tube 515 through the outer wall 606 of endograft assembly600.

Another exemplary embodiment of an endograft assembly 600 of the presentdisclosure is shown in FIG. 6D. As shown in FIG. 6D, the exemplaryendograft assembly 600 comprises a curved configuration, which may beuseful to treat, for example, a thoracic aortic aneurysm. An exemplaryembodiment of an endograft assembly 600 of the present disclosure isshown in FIG. 6E as a block diagram with identified functionalcomponents, wherein said system comprises, for example, an endograft 602comprising a graft structure 603, a tube 515, a removable catheter 612,and a suction/infusion source 614 (such as, for example, a syringe).

An exemplary endograft assembly 600, including the endograft assembly600 shown in FIG. 6A, may be used by performing the following method.Steps of an exemplary method 700 for deploying and using an endograftassembly 600 of the present disclosure are shown in FIG. 7 . As shown inFIG. 7 , method 700 may comprise the step of delivering an endograftassembly 600 to a desired site within a body, including, but not limitedto, an aneurysm sac (an exemplary delivery step 702). This step may beperformed using any number of methods for delivering endografts, stents,and/or other implantable devices within a human body, so long asremovable catheter 612 either remains affixed to tube 515 or isultimately connected to tube 515, so that a suction/infusion source 614coupled to removable catheter 612 may be used as referenced herein.After endograft assembly 600 is positioned within a vessel, graftportion 603 of endograft assembly 600 may be opened/deployed from aclosed/collapsed configuration (an exemplary deployment step 704) tosecure endograft assembly 600 within said vessel.

After endograft assembly 600 is deployed within the vessel, suction froma suction/infusion source 614 may be used (an exemplary suction step706) to withdraw, for example, blood, blood clots, and/or otherparticulates from an aneurysm sac, by way of blood and/or othermaterials entering tube openings 516 of tube 515 present within/aboutendograft assembly 600. Performance of suction step 706 may also causethe walls of aneurysm sac to collapse about endograft assembly 600. Thedegree to which said walls may collapse about endograft assembly 600depends on the relative thickness of said sac/vessel walls.

After removal of fluid from the area of interest, suction/infusionsource 614 may be used to inject a substance (an exemplary injectionstep 708) into, for example, the aneurysm sac. Such a substance maycomprise any number of biocompatible liquids including, but not limitedto, various polymers such as ethylene vinyl alcohol (EVOH) copolymer,acetate polymer, EVOH dissolved in dimethyl sulfoxide (DMSO), cellulose,various cyanoacrylates (such as 2-octyl cyanoacrylate, n-butylcyanoacrylate, iso-butyl-cyanoacrylate, and/or methyl-2- orethyl-2-cyanoacrylate, for example), various glues/(such as fibringlues, ultraviolet-light-curable glues, collagen-based glues, and/orresorcinol-formaldehyde glues, for example), various sealants (such asalbumin based sealants and/or hydrogel sealants-eosin based primerhaving a copolymer of polyethylene glycol with acrylate end caps with asealant of polyethylene glycol plus polylactic acid, for example), gelmagnetic polymer, gelatin-resorcinol-formaldehyde, styrene-derivatized(styrenated) gelatin, poly(ethylene glycol) diacrylate (PEGDA),polylactic-co-glycolic acid) (PLGA), carboxylated camphorquinone inphosphate-buffered saline (PBS), polymethylmethacrylate, vascularendothelial growth factor, fibroblast growth factor, hepatocyte growthfactor, connective tissue growth factor, placenta-derived growth factor,and/or angiopoietin-1 or granulocyte-macrophage colony-stimulatingfactor, for example.

Injection of such substances into the aneurysm sac would be performed tostrengthen/reinforce the weakened aneurysm sac walls (forming a rigid orsemi-flexible cast) to reduce the likelihood of or prevent aneurysmrupture, which can be fatal in many instances. Said substances may alsoprevent the migration of an endograft assembly 600 within the vessel byadhering to said assembly 600.

After all suction and injection steps have been performed, removablecatheter 612 would be disconnected from tube 515 (an exemplary catheterdisconnection step 710) so that the endograft assembly 600 would beseparate from removable catheter 612. Removable catheter 612 may then bewithdrawn from the patient's body (an exemplary catheter withdrawal step712), allowing the endograft assembly 600, with substance 806 (as shownin FIG. 8C, for example) positioned external to assembly 600 toreinforce weakened aneurysm sac walls, to remain within the body.

An exemplary embodiment of an endograft assembly 600 of the presentdisclosure is shown in FIGS. 8A-8C. As shown in FIG. 8A, endograftassembly 600 has been inserted, positioned, and deployed within vessel800 at a site of an aneurysm sac 802, which is presumably filled withblood, blood clots, and/or other particulates. The application ofsuction via removable catheter 612 by way of a suction/infusion source(not shown) operates to remove the blood, blood clots, and/or otherparticulates, allowing the distended vessel wall 804 to collapse orrevert back to a relatively native configuration as shown in FIG. 8B.Reinforcement of the vessel wall 804 at the site of aneurysm may beperformed by injection step 708 of the method described herein, wherebya substance 806 is injected using suction/infusion source throughremovable catheter 612, through tube 515, and out of tube openings 516into the space surrounding endograft assembly 600 at the site ofaneurysm. FIG. 8C depicts this procedure, with the black dotsrepresenting injected substance 806.

FIGS. 9A-9C show exemplary embodiments of a portion of an endograftassembly 600 and at least one embodiment of connecting and disconnectinga tube 515 of endograft assembly 600 to/from removable catheter 612(also referred to as an intra-stent graft connection). As shown in FIG.9A, an exemplary embodiment of a removable catheter 612 may comprise acatheter tip 900 configured to fit within the internal lumen 902 of tube515. Removable catheter 612, in at least one embodiment, may comprise afirst threaded portion 904 at or near the distal end 610 of removablecatheter 612, said first threaded portion 904 corresponding to a secondthreaded portion 906 within tube 515 at or near the proximal end 608 oftube 515. Tube 515, in an exemplary embodiment, may comprise one or moreunidirectional valves 908, said valves 908 permitting fluid to flow inand out of tube 515 while removable catheter 612 is coupled thereto (andwhen unidirectional valves 908 are in a first, open configuration), butpreventing fluid from flowing out of tube 515 when removable catheter612 is disconnected from tube 515 (and when unidirectional valves 908are in a second, closed configuration) as shown in FIG. 9C. Furthermore,and when unidirectional valves 908 are closed, blood from the vessel towhich endograft assembly 600 is positioned is prevented from exitingtube 515.

Removal of removable catheter 612 from tube 515 may be performed asshown in FIG. 9B. As shown in FIG. 9B, removable catheter 612 may berotated in a direction indicated by the arrow shown in the figure (orrotated in an opposite direction depending on the configuration of thefirst threaded portion 904 and the second threaded portion 906), wherebysaid rotation would allow removable catheter 612 to detach from tube515, in the direction of the arrow shown in FIG. 9C, permitting removalof removable catheter 612 from the body (at, for example, a patient'sfemoral artery). Rotation of removable catheter 612, as well asoperation of suction/infusion source 614 as referenced herein, may beperformed by a user external to a patient's body.

Additional embodiments of mechanisms for connecting and disconnectingtube 515 from removable catheter 612 are also contemplated by thepresent disclosure. Such mechanisms may include, but are not limited to,pulling removable catheter 612 with enough force to detach removablecatheter 612 from tube 515, magnetic coupling of removable catheter 612to tube 515, and other mechanisms known in the art for connecting anddisconnecting two tubes.

An additional embodiment of an endograft assembly 600 of the disclosureof the present application is shown in FIG. 10 . As shown in FIG. 10 ,endograft assembly 600 comprises an endograft 602 having an inner wall604, an outer wall 606, a graft structure 603 positioned therebetween,and further comprising a sponge sheath 1000 positioned around at least aportion of the outer wall 606 of endograft 602. Inner wall 604 definesan endograft lumen 605, as shown in FIG. 10 , permitting blood flowthrough a vessel when endograft assembly 600 is positioned therein. Inat least one embodiment, inner wall 604 is impermeable to fluids (i.e.,blood), and outer wall 606 is permeable to fluids, including blood.Sponge sheath 1000 may comprise any number of biocompatible spongy(porous) materials including, but not limited to, cellulose/wood fibers,various foamed plastic polymers, polyurethane, silastic, rubber, PTFE,synthetic sponges, natural sponges, low-density polyether (also known asthe rainbow packs of non-absorbent sponges), polyvinyl alcohol (PVA),and polyester. Sponge sheath 1000, in at least one embodiment, ispositioned circumferentially around the outer wall 606 of endograft 602,but does not cover either end of said endograft 602.

In at least one embodiment, and as shown in the exemplary embodiment ofthe endograft assembly 600 shown in FIG. 10 , one or more spongechannels 1002 are defined within sponge sheath 1000. Sponge channels1002 may, as shown in the exemplary embodiment shown in FIG. 10 , haveopen distal ends 1004 at or near the distal end 1006 of endograft 602,and the proximal ends 1008 of sponge channels 1002, at or near theproximal end of endograft 602, are in fluid communication with areservoir bag 1010 coupled to sponge sheath 1000. Sponge channels 1002may be parallel to one another (as shown in FIG. 10 ), or may comprise aperpendicular, radial, or net configuration. Reservoir bag 1010 may becollapsible, and may comprise any number of materials as referencedherein in connection with various endograft assemblies and/orcomponents.

Additional embodiments of exemplary endograft assemblies 600 (andportions thereof) of the present disclosure are shown in FIGS. 11A-11C.As shown in FIG. 11A, an exemplary endograft assembly 600 comprises anendograft 602 comprising a graft structure 603, a sponge sheath 1000(identified by the numerous ovals to visually depict the pores of asponge), and a reservoir bag 1010 coupled thereto. The endograftassembly 600 shown in FIG. 11A is shown in a collapsed configuration topermit, for example, insertion of endograft assembly 600 into a vessel.FIG. 11B shows an exemplary embodiment of an endograft assembly 600 ofthe present disclosure in an open or deployed configuration so thatendograft assembly 600 may be used within the body as referenced herein.The exemplary endograft assembly is also shown in FIG. 11B with aremovable catheter 612 removably coupled to reservoir bag 1010, so thatblood removed from the aneurysm cavity from sponge sheath 1000 thatenters reservoir bag 1010 may be removed using removable catheter 612.

A portion of an exemplary endograft assembly 600 of the presentdisclosure is shown in FIG. 11C. As shown in the portion of endograftassembly 600 shown in FIG. 11C, endograft assembly 600 comprises anendograft 602 comprising a graft structure 603, a sponge sheath 1000,and sponge channels 1002 having distal ends 1004 at the distal end 1006of endograft 602.

Additional embodiments of portions of exemplary endograft assemblies 600of the present disclosure are shown in FIGS. 12A and 12B. As shown inFIG. 12A, endograft assembly 600 comprises an endograft 602 surroundedby a sponge sheath 1000. At the distal end of endograft 602, spongechannels 1004 are visible within sponge sheath 1000 as shown in FIG.11C. FIG. 12B shows a portion of an exemplary endograft assembly 600,whereby a reservoir bag 1010 is coupled to a sponge sheath 1000 at ornear the proximal end 1200 of endograft assembly 600. A removablecatheter 612 is also shown in FIG. 12B coupled to reservoir bag 1010.Removable catheter 612 may be removably coupled to reservoir bag 1010 inthe same or similar manner as removable catheter 612 is coupled to tube515 as shown in FIGS. 9A-9C, or removable catheter 612 may be removablycoupled to reservoir bag 1010 as referenced below.

FIGS. 13A-13C show exemplary embodiments of a portion of an endograftassembly 600 and at least one embodiment of connecting and disconnectinga reservoir bag 1010 of endograft assembly 600 to/from removablecatheter 612. As shown in FIG. 13A, an exemplary embodiment of aremovable catheter 612 comprises a catheter tip 900 configured to fitwithin the internal space 1300 of reservoir bag 1010. Removable catheter612, in at least one embodiment, may comprise a first threaded portion904 at or near the distal end 610 of removable catheter 612, said firstthreaded portion 904 corresponding to a second threaded portion 1302within reservoir bag 1010. Reservoir bag 1010, in an exemplaryembodiment, may comprise one or more unidirectional valves 1304, saidvalves 1304 permitting fluid to flow in and out of reservoir bag 1010while removable catheter 612 is coupled thereto (and when unidirectionalvalves 1304 are in a first, open configuration), but preventing fluidfrom flowing out of reservoir bag 1010 when removable catheter 612 isdisconnected from reservoir bag 1010 (and when unidirectional valves1304 are in a second, closed configuration) as shown in FIG. 13C.Furthermore, and when unidirectional valves 1304 are closed, blood fromthe vessel to which endograft assembly 600 is positioned is preventedfrom exiting reservoir bag 1010. In addition, and as shown in FIGS.13A-13C, a stent graft wall 1306 may be positioned at or near theportion of reservoir bag 1010 to receive removable catheter 612, wherebystent graft wall 1306 provides reinforcement so that reservoir bag 1010does not collapse about removable catheter 612.

Removal of removable catheter 612 from reservoir bag 1010 may beperformed as shown in FIG. 13B. As shown in FIG. 13B, removable catheter612 may be rotated in a direction indicated by the arrow shown in thefigure (or rotated in an opposite direction depending on theconfiguration of the first threaded portion 904 and the second threadedportion 1302), whereby said rotation would allow removable catheter 612to detach from reservoir bag 1010, in the direction of the arrow shownin FIG. 13C, permitting removal of removable catheter 612 from the body(at, for example, a patient's femoral artery). Rotation of removablecatheter 612, as well as operation of suction/infusion source 614 asreferenced herein, may be performed by a user external to a patient'sbody.

Additional embodiments of mechanisms for connecting and disconnectingreservoir bag 1010 from removable catheter 612 are also contemplated bythe present disclosure. Such mechanisms may include, but are not limitedto, pulling removable catheter 612 with enough force to detach removablecatheter 612 from reservoir bag 1010, magnetic coupling of removablecatheter 612 to reservoir bag 1010, and other mechanisms known in theart for connecting and disconnecting a tube from a reservoir.

An exemplary endograft assembly 600, including the endograft assemblies600 shown in FIGS. 10-13C, may be used by performing the followingexemplary method 1400 for deploying and using an endograft assembly 600of the present disclosure shown in FIG. 14 . As shown in FIG. 14 ,method 1400 may comprise the step of delivering endograft assembly 600to a desired site within a body, including, but not limited, an aneurysmsac (an exemplary delivery step 1402). This step may be performed usingany number of methods for delivering endografts, stents, and/or otherimplantable devices within a body known in the art, so long as removablecatheter 612 remains affixed to reservoir bag 1010 or is ultimatelyconnected to reservoir bag 1010, so that a suction/infusion source 614coupled to removable catheter 612 may be used as referenced herein.After endograft assembly 600 is positioned within a vessel, graftportion 603 of endograft assembly 600 may be opened/deployed from aclosed/collapsed configuration (an exemplary deployment step 1404) tosecure endograft assembly 600 within said vessel.

After endograft assembly 600 is deployed within a vessel, suction from asuction/infusion source 614 may be used (an exemplary suction step 1406)to withdraw, for example, blood, blood clots, and/or other particulatesfrom an aneurysm sac, by way of blood entering sponge channels 1002 ofsponge sheath 1000 present around endograft assembly 600, enteringreservoir bag 1010, and exiting out of removable catheter 612.Performance of suction step 1406 may also cause the walls of aneurysmsac to collapse about endograft assembly 600, which depends on therelative thickness of said sac/vessel walls.

After removal of fluid from the area of interest, suction/infusionsource 614 may be used to inject a substance (an exemplary injectionstep 1408) into, for example, the aneurysm sac. Such a substance maycomprise any number of biocompatible liquids including, but not limitedto, various polymers such as ethylene vinyl alcohol (EVOH) copolymer,acetate polymer, EVOH dissolved in dimethyl sulfoxide (DMSO), cellulose,cyanoacrylates, various glues, and gel magnetic polymer. Injection ofsuch substances from removable catheter 612, through sponge sheath 1000,and into the aneurysm sac would be performed to strengthen/reinforce thealready weakened aneurysm sac walls (forming a cast) to reduce orprevent the likelihood of aneurysm rupture, which can be fatal in manyinstances. Said substances may also prevent the migration of anendograft assembly 600 within the vessel by adhering to said assembly600.

After all suction and injection steps have been performed, removablecatheter 612 would be disconnected from reservoir bag 1010 (an exemplarycatheter disconnection step 1410) so that the endograft assembly 600would be separate from removable catheter 612. Removable catheter 612may then be withdrawn from the patient's body (an exemplary catheterwithdrawal step 1412), allowing the endograft assembly 600, with asubstance 806 positioned external to assembly 600 to reinforce weakenedaneurysm sac walls, to remain within the body.

Use of an exemplary endograft assembly 600 consistent with method 1400is shown in FIGS. 15A and 15B. As shown in FIG. 15A, endograft assembly600 is positioned within a vessel 800 at the site of an aneurysm(identified by aneurysm sac 802 and distended vessel wall 804). Uponremoval of blood from aneurysm sac 802 (via suction step 1406, forexample) through sponge sheath 1000, into reservoir bag 1010, and outfrom removable catheter 612, one or more substances 806 may be injectedinto aneurysm sac 802 as shown in FIG. 15B (via injection step 1408, forexample). The injected substance 806 (represented by the black dots inFIG. 15B) may form a cast as referenced herein, reinforcing the vesselwalls 804 at the site of an aneurysm.

An exemplary embodiment of an endoprosthesis assembly 1600 of thepresent disclosure is shown in FIG. 16 . As shown in FIG. 16 ,endoprosthesis assembly 1600 comprises an endoprosthesis 1602 comprisingan inner wall 604, an outer wall 606, and optionally an additionalstructure 603 positioned between inner wall 604 and outer wall 606.Endoprosthesis assembly 1600, in such an embodiment, has an inner wall604 that is impermeable to fluids (i.e., blood), and an outer wall 606that is permeable to fluids, including blood, as described herein withrespect to various endograft assembly 600 embodiments.

A tube 515 having tube openings 516, as shown in FIG. 16 , may bepositioned upon or within outer wall 606. In at least one exemplaryembodiment, and as shown in FIG. 16 , endoprosthesis assembly 1600comprises a first tube 515 extending in various directions upon orwithin outer wall 606, such as in a back and forth “S” pattern as showntherein. Furthermore, and as shown in FIG. 16 , endoprosthesis assembly1600 may comprise one or more second tubes 1604 having tube openings 516defined therein, wherein second tube 1604 extends circumferentiallyaround or within outer wall 606. In at least one embodiment, a singletube 515 or 1604 may be used in a back and forth “S” pattern and in acomplete or partial circumferential pattern. In various otherembodiments, tubes 515 and/or 1604 may have any number of otherconfigurations about endoprosthesis 1602. As shown in FIG. 16 , forexample, the circumferential arrangement of tube(s) 1604 (noting thatmore than one tube 1604 may be present) allows for a more concentratedand/or higher quantity/volume of a casting material to be deliveredlocally to such an arrangement as described in further detail herein.

Inner wall 604 also defines a lumen 605, as shown in FIG. 16 ,permitting blood flow through a bodily vessel when endoprosthesisassembly 1600 is positioned therein. Tube openings 516 within tube(s)515, 1604, in various embodiments, are effectively exposed along and/orwithin the outer wall 606 of endoprosthesis 1602, whereby, for example,tube(s) 515, 1604 have a sealed portion for passing from the walls ofendoprosthesis 1602 into a space outside of endoprosthesis 1602. Inanother exemplary embodiment, tube(s) 515, 1604 are incorporated intoouter wall 606 so that tube openings 516 of tube(s) 515, 1604 areexposed along the outer wall 606. An exemplary endoprosthesis 1602 ofthe present disclosure may comprise any number of additional featuresthat typically or occasionally accompany endografts or endoprostheses.

As shown in FIG. 16 , the proximal end 608 of tube 515 may be removablycoupled to a distal end 610 of removable catheter 612. In various otherembodiments, removable catheter 612 may couple to other components ofendoprosthesis assembly 1600, such as, for example, tube 1604, outerwall 606, and/or one or more connectors as described in further detailherein. A suction/infusion source (not shown) may be coupled to theremovable catheter 612 at or near the distal end 610 of removablecatheter 612, so that fluid present in, for example, an aneurysm sac,may be removed by applying suction to or within removable catheter 612so that the fluid may enter tube openings 516 of tube(s) 515, 1604 asdescribed herein.

In addition, and as shown in FIG. 16 , various embodiments ofendoprosthesis assemblies 1600 of the present disclosure comprise adistal balloon 1606 and a proximal balloon 1608, said balloons 1606,1608 capable of inflation and deflation. Balloons 1606, 1608 would beeither directly or indirectly coupled to catheter 612 so that aninflation/deflation source (not shown) may be coupled to catheter 612 toinflate and/or deflate balloons 1606, 1608. For example,inflation/deflation source could be a source of carbon dioxide, saline,saline mixed with a radiopaque contrast, radiopaque dye, or another gasand/or liquid, and injection of the same could be used to inflate andsubsequently deflate balloons 1606, 1608. Use of such a substance thatis radiopaque, for example, could allow balloons 1606, 1608 to be viewedusing an angiogram, for example, so that a physician can locate theendoprosthesis assembly within the patient. As shown in FIG. 16 ,balloons 1606, 1608 are ring-shaped, so that when endoprosthesisassembly 1600 is positioned within a luminal organ, inflation ofballoons 1606, 1608 can effectively secure assembly 1600 within thevessel and can also prevent endoleak and/or leakage of casting materialpast the boundaries of endoprosthesis assembly 1600.

As shown in FIG. 16 , an embodiment of removable catheter 612 of thepresent disclosure would define multiple lumens. For example, removablecatheter 612 may define a first lumen 1610 in communication with one ormore of the first tube 515 and second tube 1604 so that asuction/infusion source coupled thereto could provide suction or injecta substance therethrough. Removable catheter 612 may further define asecond lumen 1612 indirectly or directly in communication with one ormore of balloons 1606, 1608 so that an inflation/deflation sourcecoupled thereto could be used to inflate and/or deflate balloons 1606,1608. In yet another embodiment, removable catheter 1604 may furtherdefine a third lumen 1614 to provide a casting material from a castingmaterial source. In at least another embodiment, for example, firstlumen 1610 is in communication with first tube 515, second lumen 1612 isin communication with one or more of balloons 1606, 1608, and thirdlumen is in communication with second tube 1604.

In addition to the foregoing, an optional pressure sensor 518 may besituated on the outer surface of endoprosthesis 1602 (as shown in FIG.16 , for example), or may be positioned in communication with one ormore tubes/connectors of endoprosthesis assembly 1600 to facilitatepressure measurements in the vicinity of endoprosthesis assembly 1600.Optional pressure sensor 518 may be in communication with an externaltelemetry monitoring system (not shown) via a wireless communicationsystem (not shown). Optional pressure sensor 518 may be used to indicatewhether or not a successful deployment of endoprosthesis assembly 1600has been achieved, and may also be used to monitor the patient'saneurysm by measuring the pressure therein.

Pressure sensor 518 may monitor the interior pressure of aneurysmic sac521 by measuring the local pressure outside of endoprosthesis 1602 andinside the outstretched wall of aneurysmic sac 521. This would be oftremendous clinical value as the physician can monitor the status ofaneurysmic sac 521 and adapt treatment according to aneurysmic behavior.Such a pressure sensor 518 would also have the benefit of measuringpressure during suction, so to avoid potential local negative pressures,and during injection of a substance, so to avoid excessive localpressures. In addition, pressure sensor 518 would also allow for thedetection of potential endoleak, as if, for example, the sac is vacatedand pressure is zero, an increase in pressure would indicate endoleak ifno other parameters have changed. Furthermore, the pressure due topotential endoleak could also allow a physician, for example, todetermine the desired substance/polymer pressure to counteract or opposeendoleak.

An additional embodiment of an endoprosthesis assembly 1600 of thepresent disclosure is shown in FIG. 17 . As shown in FIG. 17 , catheter612 may couple directly to outer wall 606, or may indirectly couple toouter wall 606 by way of one or more connectors (as described in furtherdetail herein) or other components so that suction from asuction/infusion source coupled to catheter 612 can cause local suctionthrough the porous outer wall 606, and infusion from thesuction/infusion source can deliver a substance through the porous outerwall 606 into a space within a luminal organ adjacent to outer wall 606.Such an embodiment of an endoprosthesis assembly 1600 as shown in FIG.17 may have features of an endograft assembly 600 of the presentdisclosure, namely the absence of tube(s) 515 and/or 1604.

In at least one embodiment, and as shown in FIGS. 18A-18C,endoprosthesis assembly 1600 is configured to obviate the need for anendograft/endoprosthesis neck and hence the necessity for a good landingzone. This is because balloons 1606 and 1608 can be inflated whenendoprosthesis assembly 1600 is positioned within a vessel at or near ananeurysm, whereby the inflation not only secures endoprosthesis assembly1600 within the vessel, but also to prevent endoleak and/or leakage ofcasting material past the boundaries of endoprosthesis assembly 1600 sothat the casting material does not leak into other areas of thepatient's vascular system.

In addition, and as shown in FIG. 18A, various endoprosthesis assemblies1600 of the present disclosure may comprise a valve mechanism 1800 tofacilitate coupling of removable catheter 612 to endoprosthesis assembly1600. Valve mechanism 1800 or removable catheter 612 may have one ormore components as shown in FIGS. 9A-9C to facilitate coupling ofremovable catheter to a portion of endoprosthesis assembly 1600, such asballoon 1606, balloon 1608, first tube 515, second tube 516, outer wall606, and the like. In at least one embodiment, valve mechanism 1800comprises a valve so that when a removable catheter 612 is coupledthereto, fluid and/or a substance can pass in either direction throughthe valve, and when removable catheter 612 is not coupled thereto, fluidand/or a substance does not pass therethrough. In at least oneembodiment, valve mechanism 1800 is a component of removable catheter612, and in another embodiment, valve mechanism is coupled to a portionof endoprosthesis assembly 1600. In an embodiment when valve mechanism1800 is not coupled to endoprosthesis assembly 1600, removal of catheter612 effectively closes off the internal tubing/connectors withinendoprosthesis assembly 1600. In at least one use of such anendoprosthesis assembly 1600, removable catheter 612 is coupled toendoprosthesis assembly 1600 at the level of the femoral artery wherethe endoprosthesis assembly 1600 is used in the case of an aorticabdominal aneurysm (AAA).

Exemplary embodiments of endoprosthesis assemblies 1600 of the presentdisclosure may be used by performing the following method. Steps of anexemplary method 1900 for deploying and using an endoprosthesis assembly1600 of the present disclosure are shown in FIG. 19 . As shown in FIG.19 , method 1900 may comprise the step of delivering an endoprosthesisassembly 1600 to a desired site within a body, including, but notlimited to, an aneurysm sac (an exemplary delivery step 702). This stepmay be performed using any number of methods for delivering endografts,endoprostheses, stents, and/or other implantable devices within a humanbody, so long as removable catheter 612 either remains affixed totube(s) 515, 1604 (or another component of endoprosthesis assembly 1600)or is ultimately connected to tube(s) 515, 1604 (or another component ofendoprosthesis assembly 1600), so that a suction/infusion source coupledto removable catheter 612 may be used as referenced herein. Afterendoprosthesis assembly 1600 is positioned within a vessel, graftportion 603 of endoprosthesis assembly 1600 may be opened/deployed froma closed/collapsed configuration (an exemplary deployment step 704) tosecure endoprosthesis assembly 1600 within said vessel.

After endoprosthesis assembly 1600 has been deployed within the vessel,distal balloon 1606 and proximal balloon 1608 may be inflated using aninflation source coupled to removable catheter 612 (an exemplary ballooninflation step 1902). Performance of balloon inflation step 1902 notonly helps to position/secure endoprosthesis assembly 1600 within thevessel, but also to isolate the aneurysm sac. As shown in FIG. 18A,endoprosthesis assembly 1600 has been delivered (by performing anexemplary delivery step 702), deployed (by performing an exemplarydeployment step 704), and balloons 1606, 1608 have been inflated (byperforming an exemplary balloon inflation step 1902) to secureendoprosthesis assembly 1600 in place.

After endoprosthesis assembly 1600 is deployed within the vessel andballoon inflation step 1902 has been performed, suction from asuction/infusion source may be used (an exemplary suction step 706) towithdraw, for example, blood, blood clots, and/or other particulatesfrom an aneurysm sac, by way of blood and/or other materials enteringtube openings 516 of tube 515 and/or tube 1604 present within/aboutendoprosthesis assembly 1600 (in an embodiment having tube(s) 515,1604), or by way of blood and/or other materials entering outer wall 606(in an embodiment not having tube(s) 515, 1604). Performance of suctionstep 706 may also cause the walls 804 of aneurysm sac 802 to collapseabout endograft assembly 600, as shown in FIG. 18B. The degree to whichsaid walls 804 may collapse about endoprosthesis assembly 600 depends onthe relative thickness of said sac/vessel walls and/or the relativesuction pressure used. In at least one embodiment, suction (to reduceoverall blood/clot volume within the aneurysm) can be measured to ensurenear zero aneurysm pressure should such a level be desired.

After removal of fluid from the area of interest, suction/infusionsource 614 may be used to inject a substance (an exemplary injectionstep 708) into, for example, the aneurysm sac. Such a substance maycomprise any number of biocompatible liquids including, but not limitedto, various polymers such as ethylene vinyl alcohol (EVOH) copolymer,acetate polymer, EVOH dissolved in dimethyl sulfoxide (DMSO), cellulose,cyanoacrylates, various glues, and gel magnetic polymer. Injection ofsuch substances into the aneurysm sac would be performed tostrengthen/reinforce the weakened aneurysm sac walls (forming a rigid orsemi-flexible cast) to reduce the likelihood of or prevent aneurysmrupture, which can be fatal in many instances. Said substances may alsoprevent the migration of an endoprosthesis assembly 1600 within thevessel by adhering to said assembly 1600. Injection step 708 may beperformed by injecting the substance through openings 516 of tube(s)515, 1604 (in embodiments of endoprosthesis assemblies having tube(s)515, 1604), or may be performed by injecting the substance through outerwall 606 (in embodiments not having tube(s) 515, 1604), as shown in FIG.18C. Injection of a substance through tube 1604, when tube 1604 is in acircumferential/ring configuration at or near the distal end ofendoprosthesis 1602, can cause more substance to be injected locally ator near the distal end (also as shown in FIG. 18C), further enhancingand/or improving the overall casting of the substance to encourage aviable cast and also to potentially prevent spreading of the aneurysmitself. FIGS. 18C and 18D depict this procedure, with the black dotsrepresenting injected substance 806. In at least one embodiment,injection step 708 is performed using injection pressure maintained ator near 30 mmHg or less, and the infused volume of substance is betweenapproximately 50 and 80 mL.

After all suction and injection steps have been performed, balloons1606, 1608 can be deflated if desired (an optional exemplary balloondeflation step 1904), as shown in FIG. 18D, and removable catheter 612would be disconnected from tube 515 or another portion of endoprosthesisassembly 1600 (an exemplary catheter disconnection step 710) so that theendoprosthesis assembly 1600 would be separate from removable catheter612. Removable catheter 612 may then be withdrawn from the patient'sbody (an exemplary catheter withdrawal step 712), also as shown in FIG.18D, allowing the endoprosthesis assembly 1600, with substance 806 (asshown in FIGS. 18C and 18D, for example) positioned external to assembly1600 to reinforce weakened aneurysm sac walls, to remain within thebody. Balloon deflation step 1904, in at least one embodiment, may beperformed within a few minutes of performing injection step 708, assubstances 806 would “cure” relatively quickly. Disconnection step 710,in at least one embodiment, causes the valve within valve mechanism 1800to close to isolate the connection between the internal components/tubesof endoprosthesis assembly 1600 from the patient's blood circulation,

Several advantages and indications exist for such an aforementionedendoprosthesis assembly 1600 (which may be referred to herein as a“single self-supporting endoprosthesis” given that only one is used at aparticular area). Exemplary indications are for chronic cases withregular size of iliac or femoral arteries to allow the use of regularintroducer sizes. Exemplary embodiments of endoprosthesis assemblies1600 allow for relatively fast insertion and localization of the landingzone since it is not important to have a “good” landing zone or neck aswith current endografts. In addition, various embodiments can be used toeffectively isolate a rupture or bleeding of the aneurysm (such as anAAA), and the solid cast ensures that the blood pressure cannot transmitto the aneurysm wall to prevent rupture. The aneurysm cast may alsoanchor the endoprosthesis assembly 1600 at the level of the aneurysmneck to eliminate migration.

Furthermore, and with respect to the foregoing, Endoleak type I iseliminated because the flow through the neck cannot be transmittedthrough the wall of the aneurysm sac due to the solid cast. Similarly,Endoleak type II is prevented because the cast physically blocks thesource arteries branches for endoleak II. In addition, the cast can bemade at pressure of about 30 mmHg, which is equal to or greater than thepressure of the endoleak arteries. Finally, the aneurysm cast supportsthe endoprosthesis assembly 1600 material and can prevent Endoleak IIIwhich typically occurs from fatigue of a typical endoprosthesis.Furthermore, such an exemplary method 1900 does not use barbs or hooksto support the endoprosthesis assembly 1600 at the level of the landingzone, thereby avoiding aortic wall lesions. The self supportingendoprosthesis assembly 1600 (balloon+aneurysm neck cast+aneurysm saccast) avoid the need for current mechanical support mechanisms.

Additional exemplary embodiments of endoprosthesis assemblies 1600 ofthe present disclosure are shown in FIGS. 20A and 20B. As shown in FIGS.20A and 20B, endoprosthesis assemblies 1600 comprise a number offeatures as shown and described in connection with other embodiments,such as distal balloon 1606, proximal balloon 1608, tubes 515, 1604defining tube openings 516, and a valve mechanism 1800. Other featuresof other embodiments of endoprosthesis assemblies 1600 of the presentdisclosure may also be present within the embodiments shown in FIGS. 20Aand 20B.

In addition, exemplary embodiments of endoprosthesis assemblies 1600 ofthe present disclosure may comprise one or more magnetic mechanisms2000, which may include one or more magnets that attract one another, orone or more magnets on one endoprosthesis assembly 1600 that attractsone or more metal components present on another adjacent endoprosthesisassembly 1600. Furthermore, and as shown in FIGS. 20A and 20B, one orboth of balloons 1606, 1608 may not be completely circumferential, asballoons 1606, 1608 extending less than 360° (such as, for example,about 180°, about 270°, or some other amount greater than about 180° butless than about 360°) may be desired so that when two endoprosthesisassemblies 1600 are positioned adjacent to one another and balloons1606, 1608 are inflated, inflation of balloons 1606, 1608 does not causethe two embodiments to separate from one another. As shown in FIG. 21 ,for example, balloons 1606 would be less than 360° around endoprosthesisassembly 16000, and balloons 1608 would remain at 360° aroundendoprosthesis assembly 1600 given their relative positioning within thebifurcated vessel.

As shown in FIGS. 20A and 20B, tubes 515 are arranged so that when bothembodiments of endoprosthesis assemblies 1600 are positioned within aluminal organ and a substance is injected therethrough to form a cast,the amount of substance that is injected between the two endoprosthesisassemblies 1600 is either significantly minimized or eliminated. It maybe desired to have some substance injected between the two embodiments(to help secure them together), but in various methods/uses, it may bedesired not to have any substance injected between the two embodimentsas such an injection may have the effect of separating the twoembodiments from one another.

FIG. 21 shows two exemplary embodiments of endoprosthesis assemblies1600 of the present disclosure positioned within a bifurcated vessel,such as near an AAA. As shown therein, a first endoprosthesis assembly1600 is positioned on a relative left side of the vessel, and a secondendoprosthesis assembly 1600 is positioned on a relative right side ofthe vessel. The proximal portions of each assembly 1600, as shown in thefigure, may be positioned within separate bifurcations, so thatinflation of proximal balloons 1608 of each assembly 1600 cause theassemblies to engage the bifurcations so that when the distal balloons1606 are also inflated and a substance is injected through assemblies1600 to form a cast, part of the cast will be in each part of thebifurcated vessel.

Several advantages and indications exist for such endoprosthesisassemblies 1600 (each of which may be referred to herein as a “doubleself-supporting endoprosthesis” given that two are used at a particulararea). Two or more endoprosthesis assemblies 1600 of the presentdisclosure, or one or more endoprosthesis assemblies 1600 and variousadditional components of the present disclosure may also be referred toherein as an “endoprosthesis system.” As shown in FIG. 21 , magneticmechanisms 2000 of each embodiment attract one another, allowing for thetwo assemblies to align and position relative to one another, andpotentially also to provide an element to be visualized using x-ray oranother visualization method. Each assembly 1600, as shown in FIG. 21 ,would be inserted (potentially simultaneously) using two differentpunctures, such as femoral or iliac punctures, wherein the assembliesshown in FIGS. 18A-18D would be inserted using a single puncture. Suchembodiments could be used for AAA sac rupture or for small femoral oriliac artery sizes allowing the use of a smaller introducer. Relativelyfast insertion could be performed without the need for a good landingzone in an emergency case of sac rupture given the presence of balloons1606, 1608 about each assembly 1600, to effectively isolate ruptureand/or bleeding of the aneurysm. Other advantages of other embodimentsof endoprosthesis assemblies 1600 of the present disclosure may alsoapply to the double self-supporting embodiments referenced herein.

A method of using such an embodiment of a double self-supportingendoprosthesis could mirror method 1900, noting that two endoprosthesisassemblies 1600 would be inserted, and an additional step of aligningthe endoprosthesis assemblies 1600 using the magnetic mechanisms wouldalso take place. For example, and as shown in the method 1900 embodimentshown in FIG. 19 , an exemplary delivery step 702 would comprise thedelivery of two endoprosthesis assemblies 1600 potentially using twoseparate punctures, and an exemplary deployment step 704 would includedeployment of both assemblies 1600. Delivery step 702 could alsocomprise alignment of the endoprosthesis assemblies relative to oneanother by way of positioning magnetic mechanisms 2000 of adjacentendoprosthesis assemblies 1600 relative to one another. One or moreremaining steps of method 1900 would be repeated for each assembly 1600used, for example.

FIG. 22 shows a block diagram of various components of exemplaryendoprosthesis assemblies 1600 (or endoprosthesis systems 2200) of thepresent disclosure. As shown in FIG. 22 , one exemplary embodiment of anendoprosthesis assembly 1600 of the present disclosure comprises a valvemechanism 1800 configured to receive part of catheter 612, and as showntherein, various connectors 2202, such as tubes, for example, are usedto couple valve mechanism 1800 to one or more of tubes 515, 1604 and/orballoons 1606, 1608. Catheter 612, as shown therein, may also be coupledto one or more of a suction/infusion source 614 and aninflation/deflation source 2204. The block diagram shown in FIG. 22 isnot intended to represent all embodiments of the present disclosure, asvarious endoprosthesis assemblies 1600 and/or endoprosthesis systems2200 of the present disclosure may include more, fewer, or no connectors2202, or may include connectors 2202 configured differently than asshown therein. In addition, various endoprosthesis assemblies 1600 andendoprosthesis systems 2200 may comprise any number of other componentsreferenced herein, such as an endoprosthesis 602, a structure 603, aninner wall 604, an outer wall 606, tube(s) 515, 1604, balloon(s) 1606,1608, a valve mechanism 1800, and/or the like.

In addition, and to visually depict various components of an exemplaryendoprosthesis assembly 1600 of the present disclosure, FIG. 23 shows ablock diagram of an exemplary endoprosthesis assembly 1600 comprising anendoprosthesis 1602, an additional structure 603, tubes 515, 104,balloons 1606, 1608, a pressure sensor 518, and a valve mechanism 1800.In addition, an exemplary endoprosthesis assembly would be configured toreceive a portion of a removable catheter 612, and would also be incommunication with, for example, a suction/infusion source 614, aninflation/deflation source 2204, and a telemetry monitor 2300 tomeasure/obtain pressure measurements from pressure sensor 518.

Several advantages to exemplary endograft assemblies 600, endoprosthesisassemblies 1600, and/or endoprosthesis systems 2200 of the presentdisclosure also include the following. First, the collapsible spongesheath 1000 of endograft assembly 600, positioned closely to theexternal surface of endograft 602, may vary its volume according to thesize of its pores and may occupy some or all of the aneurysm sac cavity.The pores within sponge sheath 1000 may facilitate the removal of bloodcontent from the aneurysm sac cavity to enter sponge sheath 1000, thuscollapsing the aneurysm sac wall about endograft assembly 600. Thecombination of sponge sheath 1000 (with its inherent pores) and spongechannels 1002 allow relatively easy removal of blood from the aneurysmsac and the injection of substances into the aneurysm sac with lowresistance. Furthermore, the collapsible sponge sheath 1000 may beuseful for all EVAR endoprosthesis procedures in order to form a castaround the endograft assembly 600, filling the aneurysm sac, andavoiding many complications such as migration, endoleak, and structuralalterations of endograft 602 produced by the stress-stretching pressurewall effect.

The various endograft assemblies 600, endoprosthesis assemblies 1600,and/or endoprosthesis systems 2200 of the present disclosure, as well ascomponents coupled thereto, may comprise any number of suitable medicalgrade materials, including, but not limited to, nitinol, variousplastics, polyurethane, silastic, polyvinylchloride (PVC), andpolytetrafluoroethylene (PTFE).

As shown in the various embodiments of endograft assemblies 600,endoprosthesis assemblies 1600, and endoprosthesis systems 2200 of thepresent disclosure, said assemblies 600, 1600 are configured to permitblood flow through the vessel for which they are placed. Said assemblies600, 1600 and systems 2200 also have the additional advantage of beingused in all EVAR endoprosthesis procedures in order to perform a castaround assemblies 600, 1600, filling the aneurysm sac and avoidingseveral complications such as Endoleak I and II and structuralalterations of the endograft assembly 600 produced by the stressstretching pressure wall effect.

Endograft assemblies 600 and endoprosthesis assemblies 1600 of thepresent disclosure may be delivered and/or positioned within a vessellumen using any number of medical tools known in the art to deliverstents and/or endografts.

Although the above exemplary embodiments of the present disclosure aredescribed in connection with treatment of aneurysms, including anabdominal aortic aneurysm, the disclosure of the present application isnot limited to its use in correcting aneurysms. Many other uses arepossible within the scope of the present disclosure. For example, thecombination of a metallic material and a corresponding magnetic devicemay be used for the correction of the structure or architecture oforgans, such as the heart or along other parts of the aorta or othervessels.

While various embodiments of devices and methods for treating aneurysmshave been described in considerable detail herein, the embodiments aremerely offered by way of non-limiting examples of the disclosuredescribed herein. It will therefore be understood that various changesand modifications may be made, and equivalents may be substituted forelements thereof, without departing from the scope of the disclosure.Indeed, this disclosure is not intended to be exhaustive or to limit thescope of the disclosure.

Further, in describing representative embodiments, the disclosure mayhave presented a method and/or process as a particular sequence ofsteps. However, to the extent that the method or process does not relyon the particular order of steps set forth herein, the method or processshould not be limited to the particular sequence of steps described.Other sequences of steps may be possible. Therefore, the particularorder of the steps disclosed herein should not be construed aslimitations of the present disclosure. In addition, disclosure directedto a method and/or process should not be limited to the performance oftheir steps in the order written. Such sequences may be varied and stillremain within the scope of the present disclosure.

The invention claimed is:
 1. An endoprosthesis assembly, comprising: anendoprosthesis having an impermeable inner wall and a permeable outerwall adjacent to the impermeable inner wall; and two elements locatedalong the endoprosthesis, said elements configured to contact a vesselwall at opposite ends of the aneurysm sac; wherein the endoprosthesisassembly is configured to be positioned relative to an aneurysm sac soto facilitate removal of blood from the aneurysm sac via a tube.
 2. Theendoprosthesis assembly of claim 1, wherein the permeable outer wall isconfigured so that fluid can flow through the permeable outer wall dueto its permeability.
 3. The endoprosthesis assembly of claim 1, whereinthe two elements comprise a first balloon and a second balloon.
 4. Theendoprosthesis assembly of claim 3, wherein the endoprosthesis assemblyis configured to isolate the portion of the luminal organ whenpositioned therein at the aneurysm sac and when the first balloon andthe second balloon are inflated.
 5. The endoprosthesis assembly of claim1, wherein the two elements comprise a first magnetic body and a secondmagnetic body.
 6. The endoprosthesis assembly of claim 5, wherein atleast part of the endoprosthesis is magnetic.
 7. The endoprosthesisassembly of claim 1, wherein the endoprosthesis assembly is configuredto permit blood present within the aneurysm sac to be removed using asuction/infusion source in communication with the endoprosthesisassembly while the endoprosthesis assembly is positioned at the aneurysmsac.
 8. A method for using an endoprosthesis assembly, the methodcomprising the steps of: introducing an endoprosthesis into a luminalorgan of a patient relative to an aneurysm sac, the endoprosthesisassembly comprising: an endoprosthesis having an impermeable inner walland a permeable outer wall adjacent to the impermeable inner wall; and afirst element located along the endoprosthesis, said first elementconfigured to contact a vessel wall at first end of the aneurysm sac;wherein the endoprosthesis assembly is configured to be positionedrelative to the aneurysm sac so to facilitate removal of blood from theaneurysm sac via a tube; and removing blood from the aneurysm sac viathe tube.
 9. The method of claim 8, further comprising the step of:isolating the aneurysm sac, prior to the step of removing blood from theaneurysm sac via the tube, by having at least the first element contactthe vessel wall at the first end of the aneurysm sac.
 10. The method ofclaim 9, wherein the endoprosthesis further comprises a second elementlocated along the endoprosthesis, said second element configured tocontact the vessel wall at a second end of the aneurysm sac opposite thefirst end, and wherein the step of isolating the aneurysm sac furthercomprises having the second element contact the vessel wall at thesecond end of the aneurysm sac.
 11. The method of claim 9, wherein thefirst element comprises a first balloon, wherein the second elementcomprises a second balloon, and wherein the step of isolating theaneurysm sac is performed by inflating the first balloon and the secondballoon.
 12. An endoprosthesis assembly, comprising: an endoprosthesishaving an impermeable inner wall and a permeable outer wall adjacent tothe impermeable inner wall; a first element located along theendoprosthesis, said first element configured to contact a vessel wallat first end of the aneurysm sac; and a second element located along theendoprosthesis, said second element configured to contact the vesselwall at a second end of the aneurysm sac opposite the first end; whereinthe endoprosthesis assembly is configured to facilitate removal of bloodfrom the aneurysm sac.
 13. The endoprosthesis assembly of claim 12,wherein the first element comprises a first balloon, and wherein thesecond element comprises a second balloon.
 14. The endoprosthesisassembly of claim 13, wherein the endoprosthesis assembly is configuredto isolate the portion of the luminal organ when positioned therein atthe aneurysm sac and when the first balloon and the second balloon areinflated.